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Genetic Exploration of Hereditary Immune Diseases
Abstract
An autoimmune disease is a condition arising from an abnormal immune response to a normal body part.
There are at least 80 types of autoimmune diseases, rheumatoid arthritis and systemic sclerosis are two
of them. My study focuses on these two diseases. Our hypothesis is that mutated genes lead to
autoimmune diseases that cause the immune system to attack the human body. The mutated genes
cause the gene expression levels to change which fail to properly regulate the body's functions, resulting
in immune system diseases. I used existing mouse models to improve the understanding of these two
diseases.
The first study concerns Arthritis (Chapter 2). This study has been designed to evaluate the molecular
mechanism that regulates spontaneous arthritis disease (SAD) in mice that are deficient in production of
interleukin 1 receptor antagonist protein (IL-1ra). Mice with a BALB/c genomic background and IL-1Ra
deficiency (BALB/c-/-) have shown susceptibility to SAD while those with a DBA/1 background are
resistant to SAD. This study was based on our data accumulated over a decade of working with this
mouse model of SAD. Our hypothesis is that there are nucleotide mutations in the gene or genes that
cause the differences in expression level between BALB/c-/- and DBA/1-/- to regulate resistance or
susceptibility to SAD. We obtained the IL-1Ra BALB/c-/- mouse model from the laboratory of Dr. John
Stuart in order to test the susceptibility of IL-1Ra deficient mice on different genetic backgrounds. By
transferring the IL-1Ra mutation onto the DBA/1 background, it was found that although BALB/c-/- mice
spontaneously developed chronic inflammatory arthritis, DBA/1 IL-1Ra–deficient (DBA/1-/-) mice did not.
We then determined the location of a genomic component that regulates susceptibility to SAD by
identifying a QTL for spontaneous arthritis on mouse chromosome 1 from a F2 population derived from
DBA/1-/- and BALB/c-/- mice. We created a congenic strain carrying the DBA/1-/- region of chromosome
1 that contains the QTL on the BALB/c-/- background. We also created a congenic strain carrying the
BALB/c-/- region of chromosome 1 that contains the QTL on the DBA/1-/- background. We then tested the
susceptibility of these strains to SAD. When the DBA/1-/- fragment was placed on a BALB/c-/background, arthritis was delayed and became less severe. When the BALB/c-/- fragment was placed on
a DBA/1-/ background, arthritis occurred in varying degrees. A study of the whole genome expression
profiles of these congenic strains and their parental strains was performed in order to identify a candidate
gene. We linked the Ifi204 gene in Ifi200 cluster to the potential causal pathway of spontaneous arthritis
in a mouse model. We identified the function of Ifi204 gene in congenic strains and their parental strains
to confirm our theory. We used state of the art technology to investigate the molecular mechanism that
regulates the susceptibility to SAD. Through this analysis, a strategy to improve the therapeutic outcome
of drugs designed based on alternative targets of the interleukin-1 (IL-1) receptor antagonist may be
identified.
The second study concerns systemic sclerosis (SSc) (Chapter 3). SSc is a polygenic autoimmune
disorder. It is of unknown etiology and is characterized by the excessive accumulation of extracellular
matrix (ECM) proteins, vascular alterations, and v
autoantibodies. The tight skin 2 (Tsk2/+) mouse model of SSc demonstrates signs similar to SSc
including tight skin and excessive deposition of dermal ECM proteins. Our hypothesis is that ENU caused
single nucleotide mutations in one or more genes in the Tsk2/+ locus interval that determines the disease
phenotype. From the literature, Tsk2/+ mice have a mutation on chromosome 1 between 42.5 and 52.5
megabases. We used microarray data to analyze the genes’ expression level to narrow down the number
of candidate genes. Based on studies of the genes’ functions, we determined that Fhl2 is our primary
candidate gene. We performed both RNA sequencing of skin transcripts and DNA sequencing of the
region spanning this gene in Tsk2/+ and wild-type littermates. As of now, we have not found any

nucleotide polymorphisms between Tsk2/+ and normal mice. We found that there are two transcripts of
this gene and they are expressed differently in the various tissues. This can help us explain why there is
only fibrosis in skin. We compared the expression levels of the two transcripts in each organ. The high
expression level of one of the transcripts in the skin can help us understand the mechanism of skin
fibrosis manifested by Tsk2/+ mice. Understanding the mechanism of skin fibrosis in the mouse model
will help us and other researchers understand the mechanism in SSc.
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ABSTRACT
An autoimmune disease is a condition arising from an abnormal immune response
to a normal body part. There are at least 80 types of autoimmune diseases, rheumatoid
arthritis and systemic sclerosis are two of them. My study focuses on these two diseases.
Our hypothesis is that mutated genes lead to autoimmune diseases that cause the immune
system to attack the human body. The mutated genes cause the gene expression levels to
change which fail to properly regulate the body's functions, resulting in immune system
diseases. I used existing mouse models to improve the understanding of these two
diseases.
The first study concerns Arthritis (Chapter 2). This study has been designed to
evaluate the molecular mechanism that regulates spontaneous arthritis disease (SAD) in
mice that are deficient in production of interleukin 1 receptor antagonist protein (IL-1ra).
Mice with a BALB/c genomic background and IL-1Ra deficiency (BALB/c-/-) have
shown susceptibility to SAD while those with a DBA/1 background are resistant to SAD.
This study was based on our data accumulated over a decade of working with this mouse
model of SAD. Our hypothesis is that there are nucleotide mutations in the gene or genes
that cause the differences in expression level between BALB/c-/- and DBA/1-/- to regulate
resistance or susceptibility to SAD. We obtained the IL-1Ra BALB/c-/- mouse model
from the laboratory of Dr. John Stuart in order to test the susceptibility of IL-1Ra
deficient mice on different genetic backgrounds. By transferring the IL-1Ra mutation
onto the DBA/1 background, it was found that although BALB/c-/- mice spontaneously
developed chronic inflammatory arthritis, DBA/1 IL-1Ra–deficient (DBA/1-/-) mice did
not. We then determined the location of a genomic component that regulates
susceptibility to SAD by identifying a QTL for spontaneous arthritis on mouse
chromosome 1 from a F2 population derived from DBA/1-/- and BALB/c-/- mice. We
created a congenic strain carrying the DBA/1-/- region of chromosome 1 that contains the
QTL on the BALB/c-/- background. We also created a congenic strain carrying the
BALB/c-/- region of chromosome 1 that contains the QTL on the DBA/1-/- background.
We then tested the susceptibility of these strains to SAD. When the DBA/1-/- fragment
was placed on a BALB/c-/- background, arthritis was delayed and became less severe.
When the BALB/c-/- fragment was placed on a DBA/1-/ background, arthritis occurred in
varying degrees. A study of the whole genome expression profiles of these congenic
strains and their parental strains was performed in order to identify a candidate gene. We
linked the Ifi204 gene in Ifi200 cluster to the potential causal pathway of spontaneous
arthritis in a mouse model. We identified the function of Ifi204 gene in congenic strains
and their parental strains to confirm our theory. We used state of the art technology to
investigate the molecular mechanism that regulates the susceptibility to SAD. Through
this analysis, a strategy to improve the therapeutic outcome of drugs designed based on
alternative targets of the interleukin-1 (IL-1) receptor antagonist may be identified.
The second study concerns systemic sclerosis (SSc) (Chapter 3). SSc is a polygenic
autoimmune disorder. It is of unknown etiology and is characterized by the excessive
accumulation of extracellular matrix (ECM) proteins, vascular alterations, and

iv

autoantibodies. The tight skin 2 (Tsk2/+) mouse model of SSc demonstrates signs similar
to SSc including tight skin and excessive deposition of dermal ECM proteins. Our
hypothesis is that ENU caused single nucleotide mutations in one or more genes in the
Tsk2/+ locus interval that determines the disease phenotype. From the literature, Tsk2/+
mice have a mutation on chromosome 1 between 42.5 and 52.5 megabases. We used
microarray data to analyze the genes’ expression level to narrow down the number of
candidate genes. Based on studies of the genes’ functions, we determined that Fhl2 is our
primary candidate gene. We performed both RNA sequencing of skin transcripts and
DNA sequencing of the region spanning this gene in Tsk2/+ and wild-type littermates. As
of now, we have not found any nucleotide polymorphisms between Tsk2/+ and normal
mice. We found that there are two transcripts of this gene and they are expressed
differently in the various tissues. This can help us explain why there is only fibrosis in
skin. We compared the expression levels of the two transcripts in each organ. The high
expression level of one of the transcripts in the skin can help us understand the
mechanism of skin fibrosis manifested by Tsk2/+ mice. Understanding the mechanism of
skin fibrosis in the mouse model will help us and other researchers understand the
mechanism in SSc.
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CHAPTER 1.

BACKGROUND AND LITERATURE STUDY

The immune system is a mechanism used to protect organisms from exogenous
attack. Without the immune system, our bodies would be open to attack from many
infectious organisms such as bacteria, viruses, parasites, among others[1, 2].
Approximately 50 million American people, around one-sixth of the U.S. population,
suffer from different forms of immune disease[3, 4]. The immune system is the one of the
most complex systems in humans. It uses cells, organs, proteins, and tissues to work in
accordance with the nervous system to keep us healthy. In the immune system,
leukocytes, also called white blood cells, are one of the most important cell types[1, 2].
Leukocytes are produced and stored in the bone marrow, thymus, lymph nodes, and
spleen. They circulate throughout organs through the lymphatic system and blood
vessels. As the leukocytes circulate throughout the body, the immune system works
efficiently to seek out and solve problems. There are two basic types of leukocytes:
phagocytes and lymphocytes. The responsibility of the phagocytes is to attack the
invading organisms, and the lymphocytes’ responsibility is to remember and recognize
the invaders and to help the body have a quick response. Lymphocytes are important
immune recognition cells[5]. They can be divided into T cells, B cells, and NK cells.
While lymphocytes are in the bone marrow, they mature to B cells. When part of a
pluripotent stem cell or pre-T cell from the bone marrow migrates into the thymus, they
differentiate and mature into immunocompetent T cells under the induction of
thymosin[6]. These two types of lymphocytes serve different functions. B cells seek out
their targets and send defenses to lock onto them, then T cells either destroy the foreign
invaders that the B cells have identified (CD8+) or they provide help to the B cells in
generating signals that give rise to antibody production (CD4+). Many immune diseases
can be detected by looking at the ratio of T cells, B cells, and other cell subpopulations[59].
An immune disease is caused by an immunoregulatory imbalance that affects the
body's immune response[1]. These diseases include structural or functional abnormalities
of the immune system that are caused by genetic and environmental factors[10].
Environmental factors include viruses, bacteria, humidity, air, and food[11, 12]. These
factors can cause immune diseases like HIV[13], rheumatoid arthritis[14], thyroiditis[15],
and diabetes[16]. Congenital immune diseases are caused by genetic defects. Many
immune diseases are caused by both environmental and genetic factors. For example,
rheumatoid arthritis is affected by temperature, humidity, and genetics[17, 18].
Autoimmune diseases are caused mainly by the accumulation of immune cells and
immunoglobulin produced by excessive immune reactions, thereby damaging normal
tissues and causing lesions and functional impairment. Scleroderma and rheumatoid
arthritis are both autoimmune diseases that have a hereditary component [19, 20]. By
comparing the genomic background of normal and diseased people, we can search for
mutated genes. Identifying the mutated genes is very helpful for the selection of
molecular targets for gene therapy.
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A gene is a sequence of DNA and is the hereditary code for proteins. Genes are
the building block of heredity: they pass from parents to children and hold the DNA and
instructions for producing proteins[21]. Genes are transcribed to RNA, which in turn are
translated to proteins that makeup living matter and are the catalysts of every single
cellular process[22]. All organisms’ physical traits are determined by these proteins. The
DNA that makes up a gene is a double-helix structure made up of Deoxyribonucleic acid,
that was first proposed by Watson and Crick in 1953[23, 24]. DNA is composed of five
organic elements – carbon, hydrogen, oxygen, nitrogen, and phosphorous – that are
organized into highly ordered substructures called nucleotides[25-27]. There are four
different nucleotides, Adenine (A)[28], Guanine (G)[29], Cytosine (C)[30], and Thymine
(T) that form the basis for DNA, and are linked by β-N-glycosidic bond from their first
carbons[28, 31]. Adenine bonds with Thymine and Cytosine bonds with Guanine. The
change in a single nucleotide can cause protein denaturation, which can cause a disease.
There are approximately 35,000 genes in the human body, and approximately 19,000 of
them are coding genes[32]. There are also approximately 35,000 genes in mice[33].
Within this huge number of genes, even one nucleotide that has been added, deleted, or
switched can cause a genetic disorder.
The proteins encoded by genes have functions that include breaking down
ingested toxins, transferring molecules, and building structures[34, 35]. Mutations in
genes can affect protein expression or the protein’s structure, thus causing a loss or
change in the function and/or excessive or insufficient expression[36, 37]. There are three
types of genetic disorders that can cause a change of the structure and function of
proteins; single gene mutations, multifactorial diseases and chromosomal abnormalities.
A single gene disorder is caused by a nucleotide mutation, deletion and/or insertion into
the coding gene[38]. The characteristics of each disease is related to the specific gene that
is affected and the role its product plays in the body. A multifactorial disease is due to
alterations in two or more genes as well as lifestyle or environmental factors. The
inheritance of these diseases is not clear; they can be inherited or sporadic[39]. A
chromosomal abnormality is a chromosomal disorder that occurs when part or all of a
chromosome is deleted or altered[40]. Down syndrome and Turner syndrome are
examples of such chromosomal disorder.
To study genetic disorders, we must understand the gene mutation causing the
disorder. A gene mutation is a permanent modification in the DNA sequence that results
in the gene coding region differing from what is found in most normal people[41]. The
change can be anywhere from a single nucleotide polymorphism to multiple large
segments on a chromosome that affects multiple genes[42]. Polymorphisms are genetic
alterations and they occur in more than one percent of DNA sequences in the human
body. Polymorphisms determine a person’s physical traits, such as their eye color, blood
type, or handedness[43, 44]. Polymorphisms are common results from natural variability
in the DNA, and most of them do not negatively affect a person’s health, although certain
mutations may increase the risk of various disorders[43]. There are two major categories
of gene mutations: hereditary and acquired. Hereditary mutations are those inherited from
a parent and they remain in a person’s cells throughout his or her life. These mutations,
also called germline mutations, are present in the parent’s germ cells as well. An acquired

2

mutation is limited to certain cells after conception[45]. In this type of mutation, the
change passes from these limited cells to their offspring cells. An acquired mutation is
caused by environmental factors, such as radiation or an error in the copying of DNA
during cell division. When the mutation is in the somatic cells, the mutation cannot be
passed to the next generation. When the mutation is in the fertilized egg, the mutation
will be delivered to the next generation, and the mutation will become a hereditary
genetic disorder. Sometimes, the mutation occurs only in the fertilized egg and will be
present in the reproductive cell but not any of the other cells. As the fertilized egg
continues to divide, each cell will also contain the mutation[46]. Genetic disorders in
which all of a child’s cells have the mutation but the parents’ do not and the disease is not
present in other family members could be the result of de novo mutations. These gene
mutations that lead to diseases are rather uncommon amongst the general population.
Protein production is initiated with transcription, where DNA is turned into RNA,
and proceeds with translation, where RNA is turned into a protein. The functions of a cell
can be determined by the amounts and types of mRNA molecules found inside the
cell[47]. The start of transcription is the main control point for gene expression[48].
Controlling the transcription initiation processes determines the types and the amounts of
proteins present in the cell. In addition, how a cell processes RNA transcripts and new
proteins can affect protein levels to a significant degree. A primary transcript synthesized
by RNA polymerase will contain a sequence that does not appear in the RNA’s final
mature form[49]. These sequences are defined as introns and are discarded before the
mature mRNA exits the nucleus. The remaining regions of the transcript contain the
protein coding region and are called exons[50, 51]. These regions are then spliced
together, and the final product is mature mRNA. Each step allows the cell to self-regulate
many of its functions through the adjustment of the amount and type of proteins it
manufactures. The quantity of any protein in a cell reflects the balance between the
synthesis and degradation biochemical pathways of said protein[48]. The gene expression
level in each tissue is relative, thus we can find the mutated gene by comparing gene
expression.
The promoter and enhancer play very important role in balancing the gene
expression level[52, 53]. The promoter is a short DNA sequence that is used to identify,
bind and initiate RNA polymerase transcription, often located about 2000 base pairs
directly upstream of the transcription initiation site[54]. To commence transcription,
RNA polymerase and other required transcription factors bind to the promoter sequence.
The promoter sequence defines the direction of transcription and indicates which DNA
strand will be transcribed; this transcribed strand is called the sense strand. The TATA
box is a promoter sequence approximately 25 to 35 base pairs above the transcription
start site[55]. Certain transcription factors will bind to the TATA box to begin the
production of an RNA polymerase transcription complex[54-56]. When there are changes
in gene expression level, we not only need to sequence the gene, but also the promoter.
Promoters sometimes have enhancers that act upon them in a cis-regulatory fashion to
either increase or decrease transcription. By interacting with promoters through DNA
looping, enhancers are able to regulate gene expression’s temporal and spatial patterns.
Enhancers can be located as much as 1,000,000 base pairs away and are 50-1500 base
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pairs in size[57, 58]. Compared to the promoter, the enhancer is not easy to find, because
it does not have an obvious feature and the range is relatively large.
When we want to study a genetic disease, we should know the whole genome
expression levels differences between the patient and normal people. Microarray
technology is a great exploratory tool, and is commonly used in both scientific and
clinical research[59]. It can help us look at the gene expression profile and can also be
used to simultaneously measure thousands of gene expression levels. DNA microarray is
a special microscope glass slide (also called gene chip) with thousands of small probes
containing a known DNA sequence or gene at defined locations. For microarray analysis,
researchers collect mRNA samples from experimental and control groups. The reference
sample is collected from a healthy individual, while the experimental sample is taken
from a diseased individual (samples are from people of the same age, gender, etc.). These
mRNA samples are then converted to complementary DNA (cDNA) and labeled with
fluorescent probes containing the color. The experimental and control samples are then
hybridized with the microarray slide. Hybridization is the process of binding a cDNA
molecule to a DNA probe on a slide. After hybridization, the expression levels of genes
are scanned by the microarray fluorescent scanner. Data analysis is done using
microarray software[59, 60]. There are two types of Microarray; one type (two-color
technique) uses red and green fluorescent dyes to hybridize experimental and control
sample separately and then load them on one chip. When gene expression levels in the
experimental sample are higher than the control sample, they will show one color
(normally red); when gene expression levels in the experimental sample are lower than
the control sample, they will show another color (normally Green). We can judge the
strength of the expression levels based on the gradient of the two colors. The data
collected by the microarray can be used to create a gene expression profile. These high or
low expressed genes will be our candidate genes. However, since microarray data only
shows the difference in expression, not the fold change, it cannot be looked at as accurate
because it may show a low difference while actually having a large fold change. Another
type of Microarray uses the one-color technique. The experimental and control samples
are separately hybridized on two chips with one fluorescent color. There are multiple
standard control probes on the chips to quantify the genes expression levels. Each probe
is quantified comparing with standard control probes, thus avoiding errors in different
batches. At the same time, each probe can determine the individual absolute expression
levels according to the standard control probes. The digital expression levels of the
experimental and control samples can be analyzed by fold changes[61, 62].
For these up or down expressed genes, an important step is to narrow down the
region to identify the mutated genes. Using the recombinant inbred (RI) strain to find the
quantitative trait locus (QTLs) that can help to narrow down the candidate genes[63-66].
RI strains are a very important and useful resources for mapping a complex trait. The RI
principle is simple and can work on many species. We use two strains to crossover,
beginning with the F2 generation, and paired to establish a new set of inbred lines
through repeated sibling mating. The RI strain has two characteristics[64, 67]. First, as
with the F2 progeny, each contains different chromosome segments randomly selected
from two progenitor cells, and thus each new strain has a random different chimera
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arrangement. Second, unlike the F2 progeny, each pair of chromosomes is homozygous
for an extension of the mosaic of alternating chromosomes derived from two progenitor
cells within each strain. The RI resource is very useful for mapping a gene of a basic
phenotype and is particularly useful for complex phenotypes such as developmental
processes, regulatory phenomena, and disease progression. The completion of the mouse
genome sequence and extensive genotyping of RI strains greatly enhanced QTL mapping
and candidate gene discovery in QTL studies[68]. The combination of RI strains and
genomic information will enable the rapid development of QTL gene discovery[67]. QTL
uses molecular marker to link the complex phenotypes with chromosomes specific region
to identify the candidate genes. Usually, a single phenotypic trait is affected by many
genes in multiple QTLs. The QTLs can be used to identify the action, interaction, and
number of genes in these precise regions. When the gene or genes are identified as
contributing to a phenotype on this region and have expression level changes. The gene
or genes can be sequenced to compare with the normal gene or genes. Basically, QTL
mapping is used to find the association between genes and the variation of a trait. The
difference between the mapping of QTL and a simple trait is that QTL needs to conduct
correlations between many genes and many small changes in the trait, which turns out to
be much more difficult to do. As the number of genes for a trait becomes larger, the
effect of each gene on the variation of the trait gets smaller. The influence of the
environment becomes important, at least in terms of the measurement of the influence of
a genetic locus. By examining the up- and down-regulation of genes and the location of
the genes on QTLs, we narrowed down the number of genes to a relatively small range,
though finding the candidate gene out of all the genes in this range still very difficult. For
some chronic diseases, it seems that the causative mutation does not exclusively appear in
well-known candidate genes.
GeneNetwork is an online software tool that can be used to search complex genes
and molecular networks to understand their functions and phenotypes[69]. Utilizing sets
of linked data to quantify the genes correlation, it can be used to study humans, mice,
rats, fruit flies, and more. There are many sequences and extensive transcriptome data
available on GeneNetwork[69-71]. It can be used to measure the extent to which genes
are correlated with the same biological substrates in genetically similar individuals.
Genetic correlations analyze gene expressions and traits within varying strains of interest.
The QTL mapping module allows users to quickly analyze traits controlled by genetic
variation and environmental factors online[70]. Genetic maps from the database can aid
in finding genetic modifiers that cause phenotypic differences. An important association
shows the presence of a QTL correlated with the tag that displays the association. Simple
interval mapping can test the association between the trait values at multiple analysis
points between each pair of adjacent marker loci and the expected genotype of the target
QTL. The bootstrap method can be performed to estimate the confidence interval at the
QTL location. Composite interval mapping and simple interval mapping is very similar.
However, unlike simple interval mapping, within each analysis point composite interval
mapping also analyzes other markers at different locations in the genome[70]. These
markers have previously been shown to be associated with traits, so we can assume that
they are close to background QTL. Paired scans evaluate all pairs of markers in the dualtrack model, including the main effects and interactions at each locus. These multiple
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QTL models can help to find complex phenotypes. For all mapping methods, the
empirical significance threshold can be determined by adding a displacement test. Some
examples include the dominance of various traits in breeding or what would happen if
only one trait is selected but other genetically related traits are expressed in unison[6971].
Genetically related assays can be applied to the same methods used to determine
heritability. There are several types of genetic correlations[72-75]. One type of
correlation is Matrix/PCA, which can compare the values of more than 100 features in
the set. The correlation matrices can then be exported, and new composite phenotypes
can be generated by using the principal component derivative of the feature set. QTL
heatmaps are another type of genetic correlation that efficiently identify common and/or
unique genetic determinants amongst large and complicated phenotypes[70]. This method
can be used to analyze up to 100 traits simultaneously, sorted either by hierarchical
clustering or their order within the genome[73]. Another type of genetic correlation,
compare dependencies, looks for shared genetic correlations in a set of features by cross
checking these traits with records across many databases. Lastly, network graphs
examine the network of associations between large phenotypes. The diagrams are
interactive, which allow users to select certain sets of features that can then be stored
briefly for further analysis in data sets such as GeneNetwork[69, 71, 72, 74].
An important step is to identify every possible genetic factor within this region. It
is essential to obtain not only accurate genome information, but also every possible
candidate gene within the genome sequences, though there are still gaps and errors in the
sequence assembly. Based on previous knowledge of its biochemical functionality and
mutant phenotypes, the candidate mutation gene was widely thought to contain alleles
causing a mutation disorder or contributing to a complex phenotype closely related to
said gene[71, 75].
Candidate gene studies use markers derived from prior hypotheses regarding the
phenotypic effect of one or multiple selected genes. The advantage of this gene approach
is that the most relevant and crucial genes will be tested[76]. Researchers use various
methods to detect such genes that are most likely to treat diseases. One method utilizes
several candidate genes that perform similar functions to find the genetic pathway.
Pathways are genes associated with drug metabolism (pharmacokinetics) and drug
reactions (pharmacodynamics)[77-79]. Researchers utilize the candidate gene pathway
strategy so that they can easily identify the effect of gene aggregation on the phenotype
with less influence of the individual gene on the downstream phenotype. Its success,
however, largely depends on the hypothesis used to select the gene to be studied[77, 79].
A risk of this method is that some genes that play an important role in pharmacokinetics
and pharmacodynamics may be passed over. In the past, candidate gene studies across all
traits have been severely lacking. Usually, diseases are linked to many different genes
and thus makes it difficult to judge whether they result from mutations or pathway
genes[41, 80].
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Candidate gene studies have often failed to determine the genetic basis of
common characteristics, suggesting that this method has some limitations[81, 82]. First,
the selection of candidate genes may not be suitable. Second, the selected SNP may
provide limited coverage and could miss several mutations. Third, the gene in question
may be located at the point of action of the selected candidate or upstream of the
downstream signaling pathway. Fourth, most of the studies are underpowered; therefore,
they face population stratification, phenotypic, and site heterogeneity issues. Lastly, and
most notably, candidate gene studies are completely reliant on past data and prior
hypotheses on disease, so it is impossible to discover genetic variants in new pathways.
Once one or a small number of candidate gene have been selected, we will
examine the difference between the candidate genes and normal genes. As we mentioned
before, the change may be only on a single nucleotide or may have a large segment
missing. Sequencing is an important method used to detect genetic mutations. The
sequencing technology can make the biological signal into a digital figure, making the
data more accessible to researchers[83, 84]. Sequencing is a method developed in 1975
by Frederick Sanger, who would later go on to win the Nobel Prize, and is thus also
commonly referred to as Sanger sequencing[85]. Sequencing is used to determine the
exact sequence of a DNA molecule. The DNA molecule itself serves as a template for its
own sequencing. DNA primers first synthesize a fragment of DNA, then the fragment is
evaluated. We used ABI Model 3130XL Genetic Analyzers with four-color fluorescencebased sequencing to detect the DNA sequence[86]. For the DNA synthesis reaction, the
key lies in the addition of a small amount of the corresponding dideoxynucleotide
triphosphates (ddNTPs) to bind A, G, T, C with the four fluorescence colors. The DNA
samples go through the four-capillary array and read the fluorescence color from the
capillary array detection, then a schematic representation of the in-capillary detection is
made. By finding the nucleotide polymorphisms between the experimental and control
group, we can calculate the changes in the amino acids. When we know the full amino
acid sequence, we get the new protein structure by protein modeling. Based on the
protein change, the protein function can also be changed.
Progress in the research of the nucleotides or protein changes help people get to
the next step in the study of immune-mediated diseases and gene therapy. It is the
introduction of exogenous normal genes into target cells to correct or compensate for
diseases caused by genetic defects and abnormalities for therapeutic purposes[87]. Gene
therapy is currently only in the laboratory stage and is thus not yet universal[88, 89].
Currently, many labs want to use the genetic material of stem cells to treat a genetic
disorder. There are several approaches to gene therapy that have been tested[87, 89].1)
Replace a disease-causing mutated gene with a healthy copy. 2) Knock out a mutated
gene that is not functioning correctly. 3) Insert a new gene into the body to help fight a
disease. The gene or genes can synthesize unique proteins, that can be used to correct
these genetic disorders. In the future, this technique can help doctors treat a disease by
inserting a gene or protein into a patient instead of using drugs or surgery[89]. Although
gene therapy shows promise as a treatment option for diseases, it is still very risky.
Currently, it is still being tested to ensure that it will be safe and effective[90].
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Animal models are useful tools to help us study human diseases. The model
usually is an animal with a disease or a phenotype similar to a human one[91]. Animal
models are widely used in genetic mapping and transgenic studies for many reasons. The
main reason for using animal models in genetic research is to obtain data that cannot be
obtained from humans[92]. One example is gene therapy: genetic material can be put into
animals, but it is not yet possible to test on humans. Genetic studies need heritable
materials such as DNA and RNA. While we can easily obtain tissues such as the liver,
heart, and brain from animals to extract RNA, it is extremely difficult to get them from
humans[92]. Several benefits to using the mouse model include: a short generation time,
a short life span, large population size, easy manipulation of environmental conditions,
diseases or conditions that can be created that are similar to the human’s, and possible
manipulation of genetic materials. However, there is also a disadvantage to using animal
models. Depending on different situations, sometimes the differences between humans
and animals are so large that the results from animal models are not reflective of those of
humans[93]. Selection of a species of animal model should not be based on availability,
familiarity, or cost, but rather on the biology, the suitability for the disease or trait, and
the impact of the study on humans. There are many animal models that have been well
developed. Mammal models have been most commonly used because of their obvious
similarities in both structures and function to those of humans [94].
The mouse is an excellent model system for understanding the development of
mammals, especially humans[95]. Mice and humans are very similar in development and
physiology, and many comparisons can be drawn between the two. There is a lot of
knowledge about human and mouse genomes. In most regions of the genome, the order
of genes, and therefore, the linkage of genes, is conserved between mice and humans.
These homologous or heterologous regions drive the advancement of human and mouse
genome projects because information about one system can be directly translated to the
other system[8, 95]. In addition, since a very large portion of the human and mouse
genomes have been sequenced, direct sequence comparisons are now possible. Moreover,
the mouse genome has been extensively characterized and its whole genome sequence
has been completed, allowing for the execution of gene-targeted “knockouts” of every
gene and transgenic over-expression in mice. We will use the mouse model to discuss the
methodology and application of animal models in QTL mapping[94].
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CHAPTER 2. GENETIC STUDY OF HUMAN RHEUMATOID ARTHRITIS
USING THE SPONTANEOUS ARTHRITIS DISEASE MOUSE MODEL1
Introduction
Rheumatoid arthritis (RA) is a common autoimmune arthritis. The disease
involves pain, swelling, and damage in the joints. Genetic and environmental factors
control the disease[96, 97]. For example, susceptible genes, humidity, and temperature all
affect RA. It is a systemic, chronic, inflammatory disorder that is presented in the wrists,
ankles, and small joints of the hands and feet. There are around 1.5 million people that
have the disease in the United States. RA normally starts between the ages of thirty and
fifty, but having the disease at any age is possible. The etiology of RA is not yet
completely known; it is a complex disease caused by many factors, with genetics and the
environment being the most important factors[98]. The chronic multi-synovial
inflammation in arthritis can cause extra-articular pathological changes[99]. RA occurs
repeatedly and is distributed symmetrically in the body. There are several stages of RA.
In the first stage, the inflammation is in the joint capsule, there is swelling in the synovial
tissues, and the symptoms include pain, swelling, and stiffness in the joint. In the second
stage, the cartilage is damaged by the inflammation of the synovial tissue. During the
third stage, inflammation is found not only in the synovium and cartilage. It also causes
bone erosion and decreases muscle strength[100]. During the last stage, the joints lose
their function and patients have the possibility of crippling. No matter which stage,
swelling and pain are always present. From the pathology, the major involvement of
rheumatoid arthritis is in the joints, and includes the synovium, cartilage, bone, muscle,
and joint ligaments[101]. Symptoms of systemic rheumatoid arthritis include fever,
fatigue, pericarditis, subcutaneous nodules, pleurisy, and peripheral neuropathy. The
inflammation also influences the other connective tissues, such as the serosa[102],
heart[103], lung[104], and eyes[105].
Studies of the genetic factors affecting arthritis have been conducted using animal
models, and research on the genetic basis of arthritis has had significant results. A rat
model was first used to report the susceptibility of multiple QTLs to regulate Collageninduced arthritis (CIA) in 1996[106]. In the study, CIA in rats and mice are both major
histocompatibility complex (MHC)-linked, and a considerable portion of arthritis cases
are caused by a non-MHC-linked molecular mechanism on other chromosomes.
Identification of genes that regulate susceptibility to non-MHC-linked arthritis is essential
for understanding the molecular mechanism of non-MHC-linked arthritis and selecting
molecular targets for therapy[107]. Many non-MHC QTLs have been located on different
chromosomes by various research groups. For example, Remmers et al. found non-MHC
QTLs in chromosomes 1, 4, 7 and 10[106]. Otto et al. identified an instructive QTL on
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Used with permission. Tian, C*, Liu, X*, et al. Ifi204 as the most favored candidate gene that
regulates susceptibility to spontaneous arthritis in mice deficient in IL-1ra. Gene Reports. 2018,
Volume 12, 21-29. *Co-first authors. doi: 10.1016/j.genrep.2018.05.006 [97].
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chromosome 8[107, 108]. They identified many QTLs on other chromosomes, scanned a
genomic mouse model of arthritis and found that it was independent of proteoglycaninduced arthritis and did not rely on a QTL associated with MHC QTL. Ibrahim’s group
used (DBA/1×FVB/N) F11/12 AIL mice to improve arthritis severity and seizures as well
as antibody responses in CIA by QTL[109]. (DBA/1×FVB/N) F2 generation has been
used to identify the QTL region[109, 110].
The major histocompatibility complex is a generic name for the gene groups that
encode the antigens of biocompatible complexes. This is a group of tightly linked gene
groups that are located in a specific region of an animal or human chromosome and are
highly polymorphic. The encoded molecules are expressed on different cell surfaces and
participate in antigen presentation, restricting mutual recognition between cells and
inducing immune responses. The names of the different species of mammalian MHC and
their encoded products vary. The MHC is called the H-2 complex in mice. Human MHC
is often referred to as human leukocyte antigens (HLA) genes or HLA complexes. Its
encoded molecules are expressed on leukocytes. The distinction between genes is often
referred to as HLA molecules or HLA antigens[111]. Progress has been made on the
study of the MHC-linked molecular mechanism of arthritis. CIA was one of the mouse
models of arthritis found to be associated with the MHC[112-114]. From the literature,
collagen induced arthritis is MHC-linked in both rats and mice[115-117]. However, there
is a portion of arthritis diseases that are not MHC-linked. Our goal is to study and
improve the understanding of the non-MHC-linked molecular mechanism that leads to
spontaneous arthritis disease[118-123]. Identification of genes that regulate via nonMHC-linked arthritis can improve our understanding of this disease and help us to choose
better molecular treatment (Figure 2-1). Many non-MHC-linked loci have been
identified, yet the causal genes for these QTLs have yet to be identified [124, 125].
Many different mouse models have been used to study non-MHC-linked arthritis.
In mice, an interleukin-1 receptor antagonist (IL-1ra) deficiency leads to spontaneous
arthritis. This serves as an important model for studying human arthritis. The
proinflammatory cytokine IL-1 is an important mediator of inflammation and arthritis in
mice. IL-1 is present in the immune system in the body[120, 126]. In animal studies,
researchers directly injected IL-1 into normal rabbit joints and this was shown to induce
severe arthritis. Treating BALB/c mice with IL-1 enhances the development of arthritis.
IL-1ra is an endogenous neuroprotectant that can inhibit IL-1. The action of IL-1ra
binding to the IL-1 receptor can prevent the IL-1receptor from binding to IL-1.
IL-1ra is a member of the Interleukin-1 gene family. It is a very important
cytokine to regulate the biologic activity of IL-1. IL-1 is produced by monocytes,
endothelial cells, fibroblasts, and other types of cells in response to infection. It is a
general term for the two different proteins IL-1α and IL-1β, both of which bind to the
same receptor in the immunoglobulin superfamily[127]. IL-1 is a regulatory and
inflammatory cytokine. In the immune system, IL-1 production can often lead to
inflammation. The role of IL-1 is not just inducing inflammation, it is also involved in
bone formation and remodeling, insulin secretion, appetite regulation, fever induction,
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Figure 2-1. MHC genomic region on mouse chromosome 17 and non-MHC QTL
loci on other chromosomes marked by molecular markers on 9 out of 19 autosomal
chromosomes.
MHC genomic region on mouse chromosome 17 and the non-MHC QTL loci have been
identified on Chromosome 1, 2, 3, 5, 6, 10, 13, 15, 17, and 18.
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neuronal phenotypic development, and IGF/GH physiology. IL-1 has been widely
reviewed, and there is an understanding of its biological activities and properties[126].
Our hypothesis is that the Ifi200 gene cluster regulates susceptibility to SAD in mice.
Within the Ifi200 cluster we focused on the Ifi204 gene. Our hypothesis is based on the
fact that expression levels of Ifi200 cluster genes decreased while resistance to SAD
increased in the congenic strain with BALB/c background, and the Ifi200 cluster genes
are the only group of genes relevant to SAD within the QTL region which showed the
differential expression[97].
IL-1ra plays an important role in regulating the effects of IL-1, which in turn
plays a significant role in the up-regulation and down-regulation of inflammation [128].
IL-1ra is a competitive and endogenous inhibitor produced by mononuclear and
macrophages. It can bind to IL-1 receptors because IL-1ra has similar affinity to IL-1α
and IL-1β. IL-1ra binds to the IL-1 receptor and blocks the activity of IL-1. IL-1ra can
terminate the inflammatory response[129]. The IL-1ra level normally increases later than
the IL-1 level in inflammatory response. Increasing the IL-1ra levels in mice can reduce
inflammation in various diseases[128].
Spontaneous arthritis disease (SAD) has been used to study rheumatoid arthritis in
humans. Horai and his coworkers showed that IL-1ra- deficient BALB/c mice develop
spontaneous arthritis[130]. Zhou developed DBA/1 mice with a deficiency in IL-1ra, but
found that the DBA/1 strain exhibits a resistance to arthritis [131]. The BALB/c and
DBA/2 strains have the same MHC haplotype, but these two strains are genetically
distanced from each other. The DBA/1 and C57BL/6J (B6) are susceptible to CIA, but
CIA cannot be induced in BALB/c mice. It is well known that DBA/1 and B6 mouse
strains have been widely used in CIA while BALB/c show resistance to CIA. SAD is
dependent on non-MHC genes in BALB/c mice that lack IL-1ra. IL-deficient mice can be
used to show the disease incidence of SAD in different mouse strains. Understanding the
molecular mechanism that leads to SAD in IL-1rn-deficient mice will represent a
breakthrough in the study of non-MHC-linked arthritis. Histopathological examination of
the ankle joints of these mice revealed inflammatory cell infiltration and synovial
proliferation in BALB/c-/-, but not in DBA/1-/- mice[132]. The bone structure and density
are also changed in BALB/c-/-, but not in DBA/1-/- mice. BALB/c-/- mice are sensitive to
nearly 100% incidence and high severity of arthritis at 7 weeks, but the DBA/1-/- mice are
resistant to spontaneous arthritis until they are very old. BALB/c-/- mice develop
spontaneous chronic inflammatory arthritis, whereas DBA/1-/- mice are resistant[97, 132].
A classic genetic technique, whole genome linkage analysis was used to detect
QTLs regulating the disease incidence and severity. Two different strains were used to
obtain the F2 generation and the QTL differences were identified between the two
parental strains[133]. F1 mice were created by intercrossing a resistant strain (DBA/1-/-)
and a susceptible strain (BALB/c-/-) of spontaneous arthritis under IL-1ra deficiency. F2
mice were used to map the QTL region that regulates IL-1ra deficient spontaneous
arthritis. There are many QTL locations to be determined because spontaneous arthritis is
a complex disease and is controlled by many genetic factors. Many pathways associated
with IL-1ra are of importance. The whole-genome mapping shows the potential QTLs of
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the disease are on chromosomes 1, 6, 11, 12 and 14. The QTL on chromosome 1 has a
major genetic effect on spontaneous arthritis in F2 mice. The pathogenic genes are
narrowed down within this QTL[133].
The F2 generation was not only used to identify the QTLs, but also continued to
generate two congenic mouse strains using BALB/c-/- and DBA/1-/- as the parental
strains. These two congenic stains can help us to understand more of the molecular
mechanisms with the parental strains[133]. Congenic strains are generated by transferring
a DNA fragment from one genetic background to a specific inbred strain through
repeated backcrossing. Backcrossing is a process where the mouse containing the donor
allele is bred with the recipient inbred partner. Recipient inbreeds are inbred lines that
provide the genetic background for the newly formed isogenic lines. The donor allele is
the allele of interest. Subsequent hybridization is the backcross of the recipient's inbred
line. Congenic strains are used because they differ by a specific chromosomal region. Our
group developed a mouse DBA.B-1-/- congenic strain with a BALB/c-/- DNA fragment in
the DBA/1-/- mouse background (by comparing the genetic markers, the genomic
transferred region is between D1Mit400/506; chromosome 1, 163,306,348 bp to the distal
end of the chromosome) and determined its susceptibility to spontaneous disease. But at a
later point, the limbs of DBA.B-1-/- congenic mice can develop inflammation. Our group
also developed a BALB.D-1-/- congenic mouse strain with a DBA/1-/- DNA fragment in
the BALB/c-/- mouse background. By comparing genetic markers, the genomic
transferred region is between D1Mit110 (chromosome 1, 167,758,517 bp) and D1Mit209
(chromosome 1, 191,493284 bp) (Figure 2-2). At approximately eight weeks of age,
limbs in BALB.D-1-/- congenic mice start to develop inflammation. The two congenic
strains were relatively susceptible to spontaneous arthritis in varying degrees. BALB.D-1/congenic mice delayed the onset and reduced the severity of disease compared to
BALB/c-/-. Compared to congenic DBA.B-1-/- and DBA/1-/-, the incidence and severity in
DBA.B-1-/- were higher than in DBA/1-/- mice[97, 131, 132, 134, 135].
Microarray gene expression analysis was used to analyze whole genome
expression profiles. This technique has been used for more than a decade and is already
very mature. This technology was used to compare the whole genome expression proﬁles
between congenic BALB.D-1-/- and DBA.B-1-/- to the four other parental strains:
BALB/c, DBA/1, DBA/1-/-, and BALB/c-/- IL-1ra deﬁcient mice. The expression levels of
the Ifi gene family had a similar change in all of the SAD susceptible mice. The Iﬁ gene
family expression levels are correlated with the resistance or susceptibility to SAD[134].
The Ifi genes in BALB.D-1-/- are lower than in BALB/c-/-, and in DBA.B-1-/- they are
higher than in DBA/1. The Ifi gene family is also in the QTL region on chromosome
1[136]. The Ifi204 gene had the most different expression levels between the susceptible
and resistant strains within the Ifi 200 family.
The interferon-activatable 200 gene cluster is a family of interferons. Interferons
(IFNs) are cytokines that regulate host resistance against infections by exerting
antimicrobial, immunomodulatory and cell growth-regulatory functions. The biological
activities of interferons are mediated by IFN-induced proteins. The Ifi200 family (lfi200
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Figure 2-2. Genomic region of the QTL on chromosome 1 and two congenic
strains.
The top part uses the F2 generation to represent the location on QTL mapping for arthritis
that has been previously identified. Numbers on the top are the genetic distance along the
chromosome. According to the genetic map, the QTL that regulate the SAD may be
located in the region between 81cM and 100cM. The bottom part depicts the transferred
genomic regions in the two congenic strains. Microsatellite markers are listed along the
chromosome as molecular markers during the congenic breeding. Below the markers are
the chromosomal components of the two congenic strains. Genomic components of
BALB/c-/- are indicated by black boxes. While the genomic components of DBA/1-/- are
indicated with red boxes. Congenic strain BALB.D1-1-/- contains a genomic region (red
boxes) from DBA/1-/- into BALB/c-/- genomic background between D1Mit55 and
D1Mit209. In congenic strain DBA.B -1-/-, the genomic region from BALB/c-/- into
DBA/1-/- strain is from D1Mit400/506 until the distal end. Based on the transferred
genomic regions in these two congenic strains, the QTL is most likely within the region
between D1mit400/506 and D1mit209.
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cluster) is encoded by several structurally related genes located on murine chromosome 1
and three homologous genes (MNDA, IFI 16 and AIM2) located in the human
chromosome, within a linkage group highly conserved between mouse and human. There
are at least six members in the Ifi200 family, designated Ifi202a, Ifi202b, Ifi203, Ifi204,
Ifi205, and Mndal. In human studies, IFI16 is connected to rheumatoid arthritis. The
arthritis mouse models were used to study the Ifi200 gene cluster to better understand the
arthritis diseases in humans. The Ifi204 gene is located from 173,747,293 to 173,766,943
bp on Chromosome 1 in the genomic QTL region[137]. It has two transcripts, but only
one can encode protein. The mRNA size of Ifi204 is 2302 bp and it consists of 9
exons[138]. The Ifi204 gene encodes a 72 kDa polypeptide whose synthesis can be
increased by treatment with IFN-α and β in several murine cell lines, with the sole
exception of those derived from the B6 inbred strain[139]. The Ifi204 protein functions as
a growth suppressor in sensitive cell lines, as determined by cell focus assays. Ifi204 is
the most important interferon-activated gene in the Ifi200 cluster for the study of
inflammation diseases in mice. The Ifi204 gene was sequenced between BALB/c-/- and
DBA/1-/-strains, and it was shown that they had multiple polymorphisms between
them[97, 140-143].
Materials and Methods
Mice
BALB/c and DBA/1 wild-type mice were purchased from the Jackson Laboratory
(Bar Harbor, ME). Animals that had an IL-1ra deficiency on the BALB/c background
(BALB/c-/-) were initially provided by Dr. Yoichiro Iwakura (Tokyo Medical and Dental
University, Tokyo, Japan)[130]. Animals that had an IL-1ra deficiency in the DBA/1
background (DBA/1-/-) were generated at the University of Tennessee Health Science
Center (UTHSC)[131]. We used congenic DBA.B-1-/- mice (BALB/c-/- fragment in
DBA/1-/- background strain) and BALB.D-1-/- (DBA/1-/- fragment in BALB/c-/background strain) mice. All mice were developed and bred in the Veterinary Medical
Unit of the Memphis VA Medical Center. All experiments followed approved laboratory
animal protocols and were approved by the VA Institutional Animal Care and Use
Committee.
Arthritis disease phenotype BALB/c-/-, DBA/1-/-, BALB.D-1-/-, and DBA.B-1-/mice were maintained in standard microisolator cages for 4 months. The severity of
arthritis was graded on each ankle joint on a scale from 0 to 4 for the degree of redness
and swelling on the left anterior limb, left posterior limb, right posterior limb, and right
anterior limb, as viewed from behind the mice. The grades: 0 = no evidence of swelling,
1 = mild swelling of the joint and/or redness of the footpad, 2 = obvious joint swelling, 3
= severe swelling of the entirety, and 4 = limb burned out and deformed. The BALB/c
and DBA/1 wild-type mice do not have SAD[132]. Each ankle joint was graded twice a
week.
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Mouse Tissue Collection
Mice were sacrificed and tissue samples collected when they were 4 months old
and all tissues were stored separately in 1.5ml tubes. The heart, muscle, liver, spleen,
lung, kidney, cerebrum, and cerebellum were put on dry ice immediately. One of the two
legs was stored in RNAlater solution (Thermo Fisher, CA) at 4 °C for a few days. The
other leg was stored in 70% ethanol in a 4 °C refrigerator. All the tissues except for the
leg stored in 70% ethanol were stored in a -80 °C freezer for subsequent experiments.
Analysis of Microarray Data
Total RNAs were isolated from the spleen in three individuals from each group
using the Trizol reagent (Invitrogen, CA) and purified using the RNAeasy Cleanup kit
(Qiagen, CA). RNAs were quantified using NanoDrop-2000 (Thermo, DE) and quality
was checked using the 2100 Bioanalyzer (Agilent, CA). The high-quality RNA was
reverse transcribed to cDNA. Then, cDNA was transcribed to cRNA by using the
Illumina® TotalPrep™ RNA Amplification Kit (Ambion, CA). For each strain, three
individual mouse samples were pooled together. The Illumina mouse-6 v1.1 expression
beadchips were used for the generation of whole genome expression profiles. Each chip
well required 1.5 μg of cRNA sample. The beadchips were hybridized overnight in a
multiple-step procedure according to the manufacturer's instructions. After washing and
drying the chips, they were scanned on the BeadArray Reader (Illumina, CA). Raw data
were analyzed using Illumina BeadStudio 2.3.41 (Illumina, CA).
Raw data were normalized using BeadStudio software. The gene expression
profiles of the two congenic strains were compared to the parental strains. The Diff Score
from the quantile method is a proprietary algorithm that uses the bead standard deviation
to build an error model; this used for the measurement of the significant difference in the
expression levels of genes. The Diff Score was set up ± 10 at initial analysis to avoid
missing the candidate genes.
Real-Time PCR
50ng total RNA was used for TaqMan real-time PCR with the Ifi204 probe
Mm00492602_m1. The TaqMan Real-Time PCR reactions were carried out with an ABI
7900 Real-Time PCR System (software: Sequence Detection System 2.3 (ABI)) using
ABI’s standard protocol for Real-Time PCR and PCR. Samples were normalized to
GAPDH expression levels. Data for treatment groups are shown as ΔΔCT normalized to
an endogenous reference.
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Rt-PCR
The expression levels of Ifi202b, Ifi203, Ifi204, Ifi205, and Mndal genes were
confirmed by endpoint rt-PCR after being determined by microarray analysis (Table
2-1). The genes expression levels were tested by using the spleen. Individual RNA
samples were separately subjected to the assay. Reverse transcription (rt) and PCR were
conducted using the One-step rt-PCR kit (Thermo Scientific, CA), as recommended by
the manufacturer. Specific primers for selected genes are designed by Primer3. The rtPCR amplified products were tested on a 1.8% agarose gel.
Sequencing Analysis
All of the chromosomal regions of interest were sequenced. Ifi204 was identified
between BALB/c-/- and DBA/1-/- mice. The primers were designed from Primer 3 online
(http://bioinfo.ut.ee/primer3-0.4.0/). Products were amplified by PCR and rt-PCR. All of
the PCR and rt-PCR products were cleaned by EXOSA-IT PCR CLEAN-UP
PROTOCOL; 5 μl PCR or rt-PCR products and 2 μl ExoSAP-IT mix were incubated at
37°C for 25 min, then at 80°C for 15min. 3 μl cleaned DNA samples, with 1 μl single
primer and 8 μl water, was used for sequencing. Samples were loaded on ABI Model
3130XL Genetic Analyzers (Thermo Fisher Scientific, CA). The data were analyzed by
Finch TV and ABI Sequence Scanning Software.
Flow Cytometry
Splenocytes: Fresh spleen tissues were stored in 1 ml RPMI 1640, LX at RT when
they were collected. Using a frosted-glass microscope slide, the spleen tissues were
gently dissociated. Spleen cell suspensions were made by hemolysis with Gey’s solution
(Gey’s stock solution: Stock A: 8.75 g NH4Cl, 0.46 g KCl, 0.27 g Na2HPO4·7H2O, 0.03 g
KH2PO4, and 1.25 g glucose in 250 ml ddH2O; Stock B: 0.42 g MgCl2·6H2O, 0.14 g
MgSO4·7H2O, and 0.45 g CaCl2·7H2O in 100 ml ddH2O; Stock C: 2.25 g NaHCO3 in
100 ml ddH2O. Gey’s Working Solution: 20% stock A, 5% stock B, 5% stock C, and
70% ddH2O). The cells were then filtered by 70 μm sterile cell strainer. Lastly, the cells
were washed with PBS 3 times and stored in 200 μl PBS. Lymphocytes: Popliteal lymph
nodes were collected from the outside of the thigh, between the skin and muscle. Cells
were dissociated using the same technique employed for spleen tissues. 200 μl PBS was
then added into the cells. Leukocytes: EL (erythrocyte lysis) buffer was used to eliminate
erythrocytes and dead cells from the blood. Purified leukocytes were placed in 200 μl
PBS. Fluorescently labeled antibodies specific for CD45 (APC-Cy7), CD3 (AlexaFluor
700), CD4 (Pacific Blue), CD8 (PE), CD19 (peridinin chlorophyll-cyanine 5.5 [PerCPCy5.5]), and CD25 (PerCP-Cy7) were obtained from BD Biosciences (San Jose, CA,
USA). Intracellular staining for Foxp3 was performed using anti-mouse Foxp3 antibody
labeled with FITC according to the manufacturer’s instructions (eBioscience, San Diego,
CA, USA). Labeled cells were washed with PBS, and a minimum of 100,000 splenic
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Table 2-1.

The Ifi202b, Ifi203, Ifi204, Ifi205, and Mndal cDNA designed primers.

Name
Ifi202b-CD1
Ifi202b-CD2
Ifi202b-CD3
Ifi202b-CD4
Ifi202b-CD5

Forward-Primer
ccggtgtcattttcttacca
agctgacacactctgccttg
tcaacagcagtggcatccta
taaaaagtaaaaagatgttccatgc
attccagcgtgtctgaggtg

Reverse-Primer
ttggctctctgtagccactgt
taggagcagcctctgacaca
tcctcgaagaccatcactctg
tttcaccattgaattggggtta
ggaacttaagcatgcagactatga

Size(bp)
480
538
544
550
550

Ifi203-CD1
Ifi203-CD2
Ifi203-CD3
Ifi203-CD4
Ifi203-CD5
Ifi203-CD6
Ifi203-CD7
Ifi203-CD8
Ifi203-CD9
Ifi203-CD10

agtctccccaggaagacagc
caaacaagagtgtaccgtcttcaa
agcaattccttcgagcagac
accatgcccagaaacatctc
tcatcaacagcatccagcag
ctcacaagcaaaggggacat
ttctaagaaatggtgctttctcat
cggggcgtactattttcaac
aaacttcctcttgcacagca
tcacagtgcaccttccagag

cctgaagtttctggaagctga
actggaagattgtggcaagg
cctggacattcttggatgct
tgaaagccctggaatagcac
aaccaccactgccatttttc
ggatagtgccaaaggcacac
tcataagccttcttcatcttgc
tgtaaacctgacaggatctgga
aatcattttcaaggttcatagcat
gaaagcaattgtgggcctta

583
583
596
588
603
577
572
600
570
556

Ifi204-CD1
Ifi204-CD2
Ifi204-CD3
Ifi204-CD4
Ifi204-CD5
Ifi204-CD6
Ifi204-CD7
Ifi204-CD8

atgaacgaaactgggaggag
gcctacctactcaagccaagc
attctggattgggcaaactg
gggacttctacagcccagaa
tgagccagtatttccatgtg
gcaaccaaagttagtgtgtgga
cctgtgtctctgatgtgaacg
ggaagactcaccaatgtcagg

aagttgttgctgagccttcc
cagtttgcccaatccagaat
cgccttgctctttttcactc
ttgatctccaggatgccttt
ttccttagcaggctcctttg
actcacaaatgtcccccttg
tctgtaattgaatcttatctccaca
gcataaaaattgcaaattgaaca

272
300
332
449
496
436
462
406

Ifi205-CD1
Ifi205-CD2
Ifi205-CD3

ccccatttttcactttctcag
cagcccagaaaaggaaaggt
aggcatcctggagatcaatg

ctgttgtgaaggacccacag
629
ccaccacttctatgcttcctg
657
tttttacagtagagaaatgaaatcaaa 624

Mndal-CD1
Mndal-CD2
Mndal-CD3
Mndal-CD4

tgtgtgtgtgtgtgtgtgctt
accgagaaggcaaaagttca
ccacccagcagttccttaaa
ctttgagagcaaaggcatcc

cagtttttgcgatcgcttt
gtattggtgactggcacctg
ccactcccctccacttctat
caaaatcagaaatcaggtatgaagg
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651
589
680
557

cells were analyzed from each sample with flow cytometry by using the SR II (BD
Biosciences).
Results
Phenotype of Mice
In the current study, DBA/1-/-, DBA.B-1-/-, BALB.D-1-/-, BALB/c-/-, DBA/1 wildtype, and BALB/c wild-type mice were bred in the animal facility under the same
conditions (Figure 2-3). The red arrows indicate the area around the ankle that is
exhibiting signs of inflammation. The phenotypes of disease for DBA/1-/-, DBA.B-1-/-,
BALB.D-1-/-, and BALB/c-/- were recorded. Mice were scored twice a week for the
condition of the disease on each ankle joint, and the scores from each ankle were added
together to calculate the cumulative clinical score for four months. The severity of
arthritis in the strains is shown in Figure 2-4A, and incidences of disease are shown in
Figure 2-4B. We knew that the phenotype of arthritic mice would be physically evident,
therefore we began scoring the ankle joint of four strains of mice at 7 weeks of age so
that we would not miss the beginning signs of arthritis. The DBA/1-/-, DBA.B-1-/-,
BALB.D-1-/-, and BALB/c-/- mice were scored from 0 to 4 on each ankle joint following
the literature. The mice were measured on day 35, 39, 42, 45, 49, 52, 56, 59, 63, 66, 70,
73, 77, 80, 84, 87, 91, 94, 98, 101, 105, 108, 112, 115, 119, and 122. BALB/c-/- and
BALB.D-1-/- mice showed swelling and redness at the ankle joints, clear arthritic
phenotypes on day 45; DBA.B-1-/- mice had mild swelling and inflammation on the hind
ankle joints as early as 10 weeks, while DBA/1-/- mice had almost no change the whole
time. These noticeable differences between the strains indicate that BALB/c-/- and
BALB.D-1-/- had phenotypic traits of arthritis, DBA.B-1-/- had a mild presentation of the
normal arthritic phenotype, and DBA/1-/- showed no phenotypic traits of arthritis. At the
4th month, the scores for both genders of each strain were averaged; BALB/c-/- male and
BALB/c-/- female scored 11.67 and 11.50; BALB.D-1-/- male and BALB.D-1-/- female
scored 10.67 and 10.60; DBA.B-1-/- male and DBA.B-1-/- female scored 3.44 and 2.32;
DBA/1-/- male and DBA/1-/- female scored 0.33 and 0.5. The males showed an earlier
progression of severity. The incidences of disease in BALB/c-/- male, BALB/c-/- female,
BALB.D-1-/- male, BALB.D-1-/- female, DBA.B-1-/- male, DBA.B-1-/- female, DBA/1-/male, and DBA/1-/- female was 100%, 100%, 100%, 100%, 86%, 67%, 33%, and 50%,
respectively, when they were 4 months old. These data, together with the visual changes
noted above, suggest that DBA/1-/- is resistant to arthritis, and that a lack of IL-1ra leads
to resistance as well. Introduction of the BALB/c-/- gene region into DBA.B-1-/- results in
a mild arthritis phenotype; BALB/c-/- and BALB.D-1-/- both have the disease. The organs
were weighed when we sacrificed them at 4 months of age (Table 2-2). In the four
strains, the males were larger than the females. Most organ weights were similar in all
four strains, but the spleens in females and males of BALB/c-/-, 0.1412 g and 0.1471 g
respectively, were larger than the other three strains. The spleen of the male DBA/1-/- was
0.1439 g, but the spleens of the other strains, besides BALB/c-/-, were ~0.11-0.12 g. The
weight of the male BALB.D-1-/- spleen (0.0973 g) was smaller than that of all other
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Figure 2-3. The phenotype of DBA/1-/-, DBA.B-1-/-, BALB.D-1-/-, and BALB/c-/strains.
Four strains of mice were bred in the UTHSC animal facility under the same conditions.
The red arrows indicate the hind ankle joints. The ankle joints from hind limbs in the
BALB/c-/- and BALB.D-1-/- strains have very severe swelling and redness at 4 months of
age. The DBA.B-1-/- mice have mild inflammation when they are 4 months of age. The
DBA/1-/- strain never had inflammation.
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Figure 2-4. Arthritis relative severity and incidence in male and female BALB/c-/-,
DBA/1-/-, BALB.D-1-/-, and DBA.B-1-/- mice.
(A) The severity of joint arthritis in both genders of four strains. The days are listed
below the horizontal axis and the severity scores are listed to the left of the vertical axis.
The BALB/c-/- mice reach maximum levels of disease severity earlier than the other
strains. The congenic BALB.D-1-/- have severe swelling and redness, but later and with
less severity than BALB/c-/- mice. BALB.D-1-/- have a later and less severe onset as a
result of the fragment of DBA/1-/- DNA. The DBA.B-1-/- mice begin to have mild arthritis
when they are ten weeks old. The severity of arthritis slowly increased over time until the
end, when it was higher. The males showed quicker progression of severity among these
three strains. The DBA/1-/- mice have almost no arthritis the entire time (n＞6). (B) The
incidence of ankle joint inflammation in the BALB/c-/-, DBA/1-/-, BALB.D-1-/-, and
DBA.B-1-/- mice. The days are listed below the horizontal axis and the incidences are
listed to the left of the vertical axis. The BALB/c-/- and BALB.D-1-/- mice have 100%
incidence at a very early stage. At nine weeks DBA.B-1-/- mice began to have incidence
of disease. DBA/1-/- showed incidence around thirteen weeks. The incidence in DBA/1-/is skewed because scoring one mouse as having swelling or redness can change the
incidence rate by a great deal. The DBA/1-/- and DBA.B-1-/- mice have lower percentages
than the BALB/c-/- and BALB.D-1-/- mice (n＞6).
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Table 2-2.

Tissue weight comparison in males and females of the four strains at time of collection. (4 months old) (n=6)

Mice

IL1ra

Weight
(g)

BL
(CM)

TL
(CM)

Liver
(g)

Spleen
(g)

Kidney
(g)

Thymus
(g)

Heart
(g)

Lung
(g)

BALB/c IL-1ra F

-/-

BALB/c IL-1ra M

-/-

DBA/1 IL-1ra F

-/-

DBA/1 IL-1ra M

-/-

BALB.D-1 IL-1ra F

-/-

BALB.D-1 IL-1ra M

-/-

DBA.B-1 IL-1ra F

-/-

DBA.B-1 IL-1ra M

-/-

21.4250±
0.6987
24.8400±
0.9289
20.6250±
1.4795
23.7200±
1.3670
20.2605±
1.8202
22.9225±
3.2306
19.0836±
1.2814
24.6382±
1.4114

8.0500±
0.2624
8.6333±
0.2517
8.2000±
0.1414
8.2000±
0.1732
8.0086±
0.4010
8.2500±
0.4212
7.8455±
0.2382
8.3727±
0.2005

8.8500±
0.2380
8.6333±
0.3055
8.0500±
0.1732
7.8667±
0.3055
8.2343±
0.4677
7.9850±
0.6011
8.1727±
0.3101
8.4727±
0.1902

1.1617±
0.0772
1.4203±
0.0748
1.2006±
0.1181
1.3153±
0.1416
0.9338±
0.1967
1.0313±
0.3043
1.0147±
0.1258
1.2769±
0.2293

0.1412±
0.0162
0.1471±
0.0484
0.1121±
0.0185
0.1439±
0.0212
0.1183±
0.0201
0.0973±
0.0279
0.1174±
0.0210
0.1201±
0.0124

0.2706±
0.0144
0.3723±
0.0432
0.2748±
0.0119
0.4314±
0.0365
0.2670±
0.0263
0.3669±
0.0644
0.2677±
0.0280
0.4773±
0.0340

0.0288±
0.0031
0.0254±
0.0047
0.0189±
0.0038
0.0132±
0.0056
0.0313±
0.0074
0.0238±
0.0065
0.0201±
0.0042
0.0154±
0.0038

0.1074±
0.0065
0.1594±
0.0305
0.1042±
0.0118
0.1199±
0.0102
0.1101±
0.0121
0.1354±
0.0276
0.1130±
0.0129
0.1446±
0.0119

0.1335±0
.0095
0.1364±0
.0096
0.1349±0
.0084
0.1347±0
.0064
0.1342±0
.0121
0.1471±0
.0198
0.1248±0
.0450
0.1375±0
.0176

IL-1ra: Interleukin 1 receptor antagonist protein. BL: body length. TL: tail length.
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strains. The weights of the other organs show no major differences. These data were
interpreted to mean that arthritis or IL-1ra was not causing the change in the spleen
weight, thus we do not know the reason for heavier spleen than that of other strains.
Expression Profile Among Different Strains
DBA.B-1-/- contains a genomic fragment from BALB/c-/- on a DBA/1-/background. Through biomarker testing, we know that it is located somewhere between
marker D1Mit506 and the distal end on chromosome 1. BALB.D-1-/- contains a genomic
fragment from DBA/1-/- on a BALB/c-/- background. Through biomarker testing, we know
that it is located between markers D1Mit55 and D1Mit426 on chromosome 1. The whole
genome gene expression similarities were compared between the two congenic mice
(DBA.B-1-/- and BALB.D-1-/-) and their parental mice (BALB/c, DBA/1, DBA/1-/-, and
BALB/c-/-) by using the mouse-6 v1.1 expression beadchip from the Illumina. The
beadchip includes 30774 probes that cover 29940 mouse genes. The R (correlation) of
expression levels of probes between DBA.B-1-/- and BALB.D-1-/- was 0.9895. (Figure
2-5A, B). The expression levels of both DBA.B-1-/- and BALB.D-1-/- were highly
correlated to that of DBA/1-/-, while DBA.B-1-/- showed more correlation than that of
BALB.D-1-/-. Because DBA.B-1-/- was deficient in IL-1ra and under the genomic
background of DBA/1-/-, its expression profile was more similar to DBA/1-/- than to any
other strain. Surprisingly, the similarity between DBA.B-1-/- and DBA/1 was less than
that between DBA.B-1 and BALB/c and BALB/c-/-, implying the possibility that the QTL
fragment from BALB/c makes the gene expression profiles of the DBA.B-1-/- similar to
that of BALB/c[97].
Gene Expression Profiling Between BALB.D-1-/- and DBA/1 Wild Type
Greater than 97% of all genes expressed by BALB.D-1-/- and DBA/1 wild type
mice showed similar expression levels. All gene expression levels were also identified in
the QTL region, and the expressions were at similar levels in the two strains. There were
264 probes down-regulated and 472 probes up-regulated in BALB.D-1-/- compared with
the expression levels of DBA/1 wild type (Figure 2-6A, B). There were 344 known
genes in these 472 up-regulated probes. By comparing the known genes in the probes
with the expression levels of DBA/1 wild type by searching on PGMapper, sixty-one out
of the 344 known genes were shown to be associated with arthritis. The Darc and Fcgr4
were located in the QTL regions. There were 189 known genes in the 264 down regulated
probes. Of these known genes, twenty-six genes were classified as arthritis related genes
by PGMapper. Three genes, Kmo, Fcr1a, and Ephx1, were within the QTL regions.
GeneNetwork was used to analyze the correlation of the sixty-one up-regulated genes,
twenty-six down-regulated genes, and the interleukin family with the UTHSC Affy
MoGene 1.0 ST spleen program. For all of these up- and down-regulated genes, no strong
correlation between these genes and the IL-1 family was found. Therefore, there was no
candidate gene that could increase the resistance to SAD, as revealed through differential
expression levels.
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Figure 2-5. Correlation of whole genome gene expression levels between DBA.B-1/, BALB.D-1-/-, and their four parental strains.
(A) Similarity between two congenic mice DBA.B-1-/- and BALB.D-1-/-. The similarity
between the two strains is 98.95%. (B) Comparison of the similarities between the two
congenic strains and their four parental strains. Strain names are listed under their
respective bars on the horizontal axis. R values are listed to the left of the vertical axis.
The gene expression profile of DBA/1 wild type has the lowest similarity with both
congenic mice, while DBA/1-/-, which has a mutation of IL-1rn and is under the DBA/1
genomic background, has the highest similarity to both congenic strains. The BALB.D-1/has more similarity with BALB/c background mice (BALB/c wild type and BALB/c-/-)
than with DBA.B-1-/- mice.
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Figure 2-6. Up and down regulated genes in BALB.D-1-/- mice in comparison to
that of DBA/1 wild type mice.
(A) Downregulated genes in BALB.D-1-/- mice compared with DBA/1 wild type. The
gene names are shown below the horizontal axis. Numbers to the left of the vertical axis
are the fold changes. There are 264 probes downregulated and 189 of them are known
genes. Twenty-six of them are related to arthritis and three of them (Kmo, Fcr1a, and
Ephx1) are on QTL region. (B) Upregulated genes in BALB.D-1-/- mice compared with
DBA/1 wild type. The gene names are shown below the horizontal axis. Numbers to the
left of the vertical axis are the fold changes. There are 472 probes upregulated and 344 of
them are known genes. Sixty-one of them are related to arthritis and two of them (Darc
and Fcgr4) are on a QTL region.

25

Gene Expression Profiling Between BALB.D-1-/- and DBA/1-/There was approximately 99% similarity between BALB.D-1-/- and DBA/1-/mice. Both lack the IL-1rn gene. The gene expression levels in BALB.D-1-/- and DBA/1/showed more similarities compared to BALB.D-1-/- and DBA/1 wide type mice. There
were 241 probes down-regulated and 310 probes up-regulated in BALB.D-1-/- (Figure
2-7A, B). 235 of the 310 up-regulated probes were known genes. From PGMapper, fortythree known genes were related to arthritis. There were 212 known genes in the 242
down-regulated probes. Twenty-nine of these known genes were related to arthritis
according to PGMapper. Forty-three upregulated and twenty-nine downregulated probes
and IL-1rn family genes were identified using the UTHSC Affy MoGene 1.0 ST Spleen
program. BALB.D-1-/- compared with DBA/1-/- was very similar to the DBA wild type
mice. There were none directly related to the IL-1 family.
After eliminating duplicate probes, there were 101 probes left to analyze. Similar
to the DBA wild type mice, the data analysis of the gene network showed no strong
correlation between these genes and the IL-1rn family. Thus, there was no candidate gene
to account for the increased susceptibility to SAD.
Gene Expression Profiling Between BALB.D-1-/- and BALB/c Wild Type
Between the BALB.D-1-/- and BALB/c wild type mice, the similarity between
them were around 98.8%. There were seventy probes up-regulated and thirty-one probes
down-regulated (Figure 2-8A, B). Among the seventy up-regulated probes, all were from
known genes and among the thirty-one down-regulated probes, thirty were from known
genes. In these changing genes, Siglec1 was only one associated with arthritis. Ifi202b
was one of the up-regulated genes and was found in the QTL region. Ifi203 was one of
the down-regulated genes and was also located in this QTL region. In these ninety-two up
and down regulated probes, there was no correlation to the Interleukin-1 family by
GeneNetwork. There was no candidate gene between BALB.D-1-/- and BALB/c wild type
mice.
Gene Expression Profiling Between BALB.D-1-/- and BALB/c-/The similarity between BALB.D-1-/- and BALB/c-/- was 99%. There were twelve
down-regulated probes and no up-regulated probes. Eight of the twelve down-regulated
probes were known genes (Figure 2-9). These nine genes are LOC100040462 (Mndal),
LOC639001, Ifi203, LOC665425, Lefty1, Trbc6, LOC638301, Ifi204, and Ifi202b. There
was no relationship between these genes and arthritis using PGMapper. The Ifi202b,
Ifi203, Ifi204, Mndal, and Lefty1 genes are located in the QTL region on chromosome 1.
In comparing these genes with the IL-1 family, there is no strong correlation between the
IL-1rn and the interferon-activatable protein family members. Searching the genetic
pathway and gene correlation, the T-cell receptor beta chain gene was not in the QTL
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Figure 2-7. Up and down regulated genes in BALB.D-1-/- mice in comparison to
that of DBA/1-/- mice.
(A) Downregulated genes in BALB.D-1-/- mice compared with DBA/1-/-. The gene
names are shown below the horizontal axis. Numbers to the left of the vertical axis are
the fold changes. There are 241 probes downregulated and 212 of them are known genes.
Twenty-nine of them are related to arthritis. (B) Upregulated genes in BALB.D-1-/- mice
compared with DBA/1-/-. The gene names are shown below the horizontal axis. Numbers
to the left of the vertical axis are the fold changes. There are 310 probes upregulated and
235 of them are known genes. Forty-three of them are related to arthritis.
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Figure 2-8. Up and down regulated genes in BALB.D-1-/- mice in comparison to
that of BALB/c wild type mice.
(A) Downregulated genes in BALB.D-1-/- mice compared with BALB/c wild type. The
gene names are shown below the horizontal axis. Numbers to the left of the vertical axis
are the fold changes. There are thirty-one probes downregulated and thirty of them are
known genes. None of them are related to arthritis. (B) Upregulated genes in BALB.D-1-/mice compared with the BALB/c wild type. The gene names are shown below the
horizontal axis. Numbers to the left of the vertical axis are the fold changes. There are
seventy probes upregulated and all of them are known genes. Only one of them (Siglec1)
is related to arthritis. Ifi202b is one of the upregulated genes and Ifi203 is one of the
downregulated genes located in this QTL region.
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Figure 2-9. Down regulated genes in BALB.D-1-/- mice in comparison to that of
BALB/c-/- mice.
There are twelve probes downregulated and no probes upregulated when BALB.D-1-/- is
compared with BALB/c-/- mice. The gene names are shown below the horizontal axis.
Numbers to the left of the vertical axis are the fold changes. There are twelve probes
downregulated and nine of them are known genes. None of them are related to arthritis,
but there are five of them (Ifi202b, Ifi203, Ifi204, Mndal, and Lefty1) that are located in
the QTL region on chromosome 1.
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region, but the T-cell receptor beta chain gene was positively associated with the Ifi
family. The location of Ifi202b, Ifi203, Ifi204, Mndal, and Lefty1 genes in the QTL
region indicate that these could be the candidate genes.
Gene Expression Profiling Between DBA.B-1-/- and DBA/1 Wild Type
Comparing DBA.B-1-/- to DBA/1 wild type mice, there was around 97%
similarity between DBA.B-1-/- and DBA/1 wild type. Compared to the expression levels
of DBA/1 wild type, there were 255 up-regulated probes and thirty-six down-regulated
probes in DBA.B-1-/-(Figure 2-10A, B). From these probes, 194 of 255 up-regulated
probes were known genes and twenty-eight of thirty-six down-regulated probes were
known genes. The data of DBA.B-1-/- and its parental strain were very different from
BALB.D1-1-/- and its parental strain, where the number of down regulated genes was
much larger than that of up-regulated genes. Forty of the up-regulated probes were
located on chromosome 1 and five of them are within the transferred genomic region.
They are: Dermatopontin (dpt); Integrator complex subunit 7 (ints7); CDNA sequence
BC055324 (bc055324); Interferon activated gene 203 (Ifi203); and Fc receptor, IgG, low
affinity IV (fcgr4). By searching PubMed using PGMapper, there was only the HtrA
serine peptidase 1 (htra1) down-regulated gene related to arthritis, but this gene was on
chromosome 7. There were no genes located in the QTL region.
Gene Expression Profiling Between DBA.B-1-/- and BALB/c Wild Type
Between the DBA.B-1-/- and BALB/c wild type mice, the similarity was more
than 97.5%. There were 305 probes with down-regulated expression levels and 336
probes with up-regulated expression levels when DBA.B-1-/- was compared with BALB/c
wild type mice (Figure 2-11A, B). The number of up and down regulated genes were
many greater than that found in BALB.D1-1-/- when it was compared to BALB/c. These
data are reasonable considering the fact that DBA.B-1-/- is under the background of a
different genome. 164 of 336 up-regulated probes were known genes in DBA.B-1-/-, and
seventy-one of them were reported as relevant to arthritis by PGMapper. Ten genes were
located on chromosome 1; however, only one gene, Epoxide hydrolase 1 (ephx1), was
located in the QTL region. In these 305 down-regulated probes, there were 214 known
genes. Fifty of these known genes were relevant to arthritis according to PGMapper.
Eleven genes were on chromosome 1 and three of them were located within the QTL
region. They were Olfactomedin-like 2B (olfml2b), Selectin platelet (selp), and Low
affinity immunoglobulin gamma Fc region receptor IV (fcgr4).
These four genes on QTL, along with IL-1rn family genes were analyzed for their
gene correlation using the same whole genome expression profiles of spleen used above
for DBA/1. One probe was found for each of the twelve genes. GeneNetwork indicated
that the expression levels of all four genes are positively correlated with the expression
levels of genes in the IL-1rn family.
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Figure 2-10. Up and down regulated genes in DBA.B-1-/- mice in comparison to
that of DBA/1 wild type mice.
(A) Downregulated genes in DBA.D-1-/- mice compared with DBA/1 wild type. The gene
names are shown below the horizontal axis. Numbers to the left of the vertical axis are
the fold changes. There are thirty-six probes downregulated and twenty-eight of them are
known genes. One of them (htra1) is related to arthritis. (B) Upregulated genes in
DBA.D-1-/- mice compared with DBA/1 wild type. The gene names are shown below the
horizontal axis. Numbers to the left of the vertical axis are the fold changes. There are
255 probes upregulated and 194 of them are known genes. Forty of them are related to
arthritis and five of them (dpt, ints7, bc055324, Ifi203, and fcgr4) are on a QTL region.
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Figure 2-11. Up and down regulated genes in DBA.B-1-/- mice in comparison to that
of BALB/c wild type mice.
(A) Downregulated genes in DBA.D-1-/- mice compared with BALB/c wild type. The
gene names are shown below the horizontal axis. Numbers to the left of the vertical axis
are the fold changes. There are 305 probes downregulated and 214 of them are known
genes. Fifty of them are related to arthritis. There are eleven genes on chromosome 1 and
three of them (olfml2b, selp, and fcgr4) are in the QTL region. (B) Upregulated genes in
DBA.D-1-/- mice compared with BALB/c wild type. The gene names are shown below
the horizontal axis. Numbers to the left of the vertical axis are the fold changes. There are
336 probes upregulated and 164 of them are known genes. Seventy-one of them are
related to arthritis. There are ten genes on chromosome 1 and only one of them (ephx1) is
in the QTL region.
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Gene Expression Profiling Between DBA.B-1-/- and BALB/c-/The similarity of DBA.B-1-/- and BALB/c-/- mice was around 98%. In expression
levels, there were 231 probes down-regulated and 158 probes up-regulated when DBA.B1-/- was compared with BALB/c-/- (Figure 2-12A, B).
There were 153 known genes in these 231 down-regulated probes. Thirty-three of
those known genes were connected to arthritis by using the PGMapper. Among the 158
up-regulated genes, 109 were known genes. Twenty-seven of these genes were arthritisrelevant. However, none of these up or down-regulated genes are located in the QTL
region on chromosome 1. This result is significantly different from the data which
compared BALB.D-1-/- to BALB/c-/-, where only a few genes, mainly Ifi family members,
were down regulated in BALB.D1-1-/-. Probes for Ifi204, Ifi205, and Fcgr4 were
identified from the spleen genome expression profile. They were used to construct a gene
network with genes of the IL-1rn family. The gene network indicated that Ifi204 and
Ifi205 are weakly positively correlated to the genes of the IL-1rn family while hsph1 is
not. None of these genes have a relationship to arthritis. Among these differentially
expressed genes, the Ifi cluster is located within the transferred QTL genomic region.
Gene Expression Profiling Between DBA.B-1-/- and DBA/1-/There was about 97% similarity between DBA.B-1-/- and DBA/1-/-; both of them
lack the IL-1rn gene. Comparing the expression levels of DBA.B-1-/- to DBA/1-/-, there
were only three down-regulated probes and five up-regulated probes (Figure 2-13). In
these three down-regulated genes, one was heat shock 105kDa/110kDa (hsp105/110hDa).
Another one was immunoglobulin kappa variable 2-112 (Igkc2-112). There was no useful
information about the third one. In the five up-regulated genes, three of them are for
interferon-activatable proteins (Ifi). LOC100040462 is a predicted new gene for
interferon-activatable proteins called myeloid nuclear differentiation antigen like
(Mndal). LOC100044430 is predicted as Ifi205, and LOC638301 is predicted as Ifi204,
because the probes and the genes have the same sequence. The Ifi family genes had a
highly up-regulated expression level in DBA.B-1-/- that compares favorably with that of
DBA/1-/-.
Interferon-activatable Protein Gene Expression Levels in BALB.D-1-/- and
DBA.B-1-/- Compared with the Four Parental Strains
Ifi gene expression levels of the BALB.D-1-/- strain were compared with the four
parental strains. The Ifi gene family expression levels in the BALB.D-1-/- strain were
lower than BALB/c-/- and BALB/c, but there was no significant difference between the
other two strains, DBA/1-/- and DBA/1 (Figure 2-14A). A lower expression level in the
candidate genes would be expected because BALB.D-1-/- has the genetic fragment from
DBA/1-/-. The differences in expression levels of the Ifi family genes between DBA.B-1-/and DBA/1 are similar to that of DBA.B-1-/- and DBA/1-/-. However, there is no
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Figure 2-12. Up and down regulated genes in DBA.B-1-/- mice in comparison to that
of BALB/c-/- mice.
(A) Downregulated genes in DBA.D-1-/- mice compared with BALB/c-/-. The gene
names are shown below the horizontal axis. Numbers to the left of the vertical axis are
the fold changes. There are 231 probes downregulated and 153 of them are known genes.
Thirty-three of them are related to arthritis. None of them is in the QTL region on
chromosome 1. (B) Upregulated genes in DBA.D-1-/- mice compared with BALB/c wild
type. The gene names are shown below the horizontal axis. Numbers to the left of the
vertical axis are the fold changes. There are 158 probes upregulated and 109 of them are
known genes. Twenty-seven of them are related to arthritis. None of them is in the QTL
region on chromosome 1.
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Figure 2-13. Up and down regulated genes in DBA.B-1-/- mice in comparison to that
of DBA/1-/- mice.
Up- and downregulated genes in DBA.D-1-/- mice compared with DBA/1-/-. The gene
names are shown below the horizontal axis. Numbers to the left of the vertical axis are
the fold change. There are only 3 downregulated probes and 5 upregulated probes. Two
of the downregulated genes (hsp105/110hDa and igk2-112) are known. Three of the
upregulated genes are from Ifi family (Mndal, Ifi205, and Ifi204).
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Figure 2-14. Gene expression levels of Ifi family congenic strain BALB.D-1-/- and
DBA.B-1-/- in comparison with four parental strains.
(A) Ifi family gene expression in BALB.D-1-/- compared with four other strains. The
strains are shown below the horizontal axis. Numbers to the left of the vertical axis are
the fold changes. Ifi protein, Ifi202b, Ifi203, Ifi204, and Ifi205 expression levels in
BALB.D-1-/- are downregulated in comparison with that of BALB-/- and BALB/c (except
the Ifi202b is upregulated when BALB.D-1-/- is compared with BALB/c), but no
significant difference compared to the other two strains, DBA/1-/- and DBA/1. (B) Ifi
family gene expression in DBA.B-1-/- compared with four parental strains. The strains are
shown below the horizontal axis. Numbers to the left of the vertical axis are the fold
change. Ifi protein gene expression was similar to-Ifi204, and similar to Ifi205;
expression levels in DBA.B-1-/- are upregulated in comparison with that of DBA/1-/- and
DBA/1, but no significant difference in comparison to the other two strains, BALB-/- and
BALB/c wild type.
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significant difference between any of the genes when comparing with BALB/c and
BALB/c-/- because DBA.B-1-/- has the genetic fragment from BALB/c-/- that contains the
Ifi family genes (Figure 2-14B). DBA.B-1-/- has higher expression levels of Ifi204 in
comparison to DBA/1-/- and DBA/1 because it has the genetic fragment from BALB/c-/-.
The Potential Involvement of Interferon-activatable Protein Genes in the Regulation
of Susceptibility to SAD
DBA/1-/- is resistant to SAD, whereas BALB/c-/- is susceptible to SAD. The
increase in expression levels of the Ifi family genes in the DBA.B-1-/- strain resulted in a
decrease in resistance to arthritis compared to DBA/1-/- mice. The decreased Ifi family
gene expression levels in the BALB.D-1-/- strain also showed increased resistance
compared to the BALB/c-/- mice. Our multiple comparisons confirmed that the increased
Ifi gene cluster expression levels in DBA.B-1-/- constitute the major change that
potentially leads to increased susceptibility to SAD, and the conversely – decreased Ifi
gene cluster expression levels in BALB.D-1-/- – constitute the major change that
potentially leads to increased resistance to SAD. The BALB/c and BALB/c-/- (susceptible
to SAD) strains had higher Ifi gene expression levels than the DBA/1 and DBA/1-/- strains
(resistant to SAD). Based on gene expression levels and QTL analysis, the Ifi200 gene
family was determined to be our candidate gene family for SAD. Among differentially
expressed genes between congenic strains and parental strains, three genes in the Ifi
family cluster were differentially expressed and are located in the transferred genomic
fragments in the congenic strains. These genes are in the QTL genomic fragment on
chromosome 1, which is found between 173,747,293 (Ifi204) bp and 174,031,810
(Ifi205) bp. The transferred region from BALB/c-/- to DBA/1-/- background in the
congenic DBA.B-1 strain is from 163,306,348bp (D1mit506) to the distal end of
chromosome 1. The transferred region contains several hundreds of genes and other
genetic elements. None of the probes of other genes showed a significant change in the
expression level between DBA.B-1 and DBA/1-/-, while three probes of the Ifi family
were upregulated in DBA.B-1-/-. Research has shown that interferon-activatable protein is
an immune suppressor in viral infection[97, 128].
The Ifi204 as the Most Favorable Candidate Gene for SAD
The Ifi200 genes are located next to each other and are known to be located in the
identified QTL region. Rnpep is located outside of the QTL, therefore, it is eliminated as
a candidate for SAD. Lefty1 is within the QTL, but there is no indication of it having a
role in arthritis. In comparison to Ifi200 genes, Lefty1 is of a lower priority.
In order to explore whether all of the genes in Ifi200 or one or two other genes
regulate SAD, we examined the expression levels of these genes in congenic DBA.B-1-/and DBA/1-/- strains (Figure 2-15A). To our surprise, among these genes, only the
expression levels of Ifi204 were at meaningful levels. The other genes were detected at
very low levels, indicating that they either express at a minimum level or not at all. We
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Figure 2-15. Comparison of expression levels of genes in Ifi family.
(A) Relative expression levels of Ifi family genes compared between DBA.B-1-/- and
DBA/1-/-. The gene names are shown below the horizontal axis. Numbers to the left of the
vertical axis are the scores of relative expression. Ifi202b gene expression in DBA.B-1-/is lower than DBA/1-/-. Ifi204 and Ifi205 gene expressions are similar between DBA.B-1/and DBA/1-/-. Ifi203, LOC100044430-Ifi205, and LOC638301-Ifi204 gene expressions
in DBA.B-1-/- are higher than in DBA/1-/-. Ifi204 gene expression is twice as high in
DBA.B-1-/- than in DBA/1-/-. (B) Relative expression levels of Ifi family genes compared
between DBA.B-1-/- and DBA/1-/-. The gene names are shown below the horizontal axis.
Numbers to the left of the vertical axis are the scores of relative expression. Ifi202b gene
expression in BALB.D-1-/- is higher than in BALB/c-/-. Ifi204 and Ifi205 gene
expressions are similar between BALB.D-1-/- and BALB/c-/-. Ifi203, LOC100044430Ifi205, and LOC638301-Ifi204 gene expressions in BALB.D-1-/- are lower than in
BALB/c-/-.
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further examined the expression levels of these genes in congenic BALB.D1-1-/- and
BALB/c-/- strains (Figure 2-15B). Among these genes, only the expression of Ifi204 was
at a meaningful level. The other genes were detected at very low levels. In order to
answer the question concerning whether it is possible that the low expression levels of
other Ifi cluster genes are the results of cross hybridization among genes in the Ifi200
cluster, we compared the sequences of the probe of Ifi204 with the sequences from other
genes in the Ifi200 cluster. Our blast search showed a high similarity of genes among the
Ifi200 cluster[97].
The Potential Connection Between Ifi204 and Differentially Expressed Genes within
QTL Regions and Arthritis Relevant Genes
By comparing congenic to parental strains, we identified differential genes within
QTL regions and genes that are relevant to arthritis. Our final question was, what was the
relationship between Ifi204 and these differentially expressed genes? Any potential
association was explored between Ifi204 and these genes. The genes being compared
were Dpt, Ints, bc055324, fcgr4, and htra1 from the comparison between DBA.B-1-/- and
DBA/1 wild type; ephx1, olfml2b, selp, and fcgr4 from the comparison between DBA.B1-/- and BALB/c wild type; Fcgr4 and Ifi205, from the comparison between DBA.B-1-/and BALB/c-/-; hsp105/110hDa, Igkc2-112, and Mndal from the comparison between
DBA.B-1-/- and DBA/1-/-.
A graphic gene network created using the literature was made, based on gene
expression levels. The expression level of Ifi204 is only weakly positively connected to
that of Fcgr4, with an R value of 0.405, suggesting that the expression level of this gene
is not strongly influenced by Ifi204 (Figure 2-16A). This network indicated that the
majority of these genes were studied or were reported with Ifi204, suggesting that their
functions are potentially connected to that of Ifi204 (Figure 2-16B). In particular, Htra1
was linked to arthritis through the destruction of the extracellular matrix causing a
degradation in cartilage[144]. As seen in the figure, Htra1 is strongly connected to Dpt
with a very high positive correlation value, and two of them were found to both be highly
enriched in hip cartilage[145]. Htra1 and Dpt are also connected to Ifi204 with a high
positive correlation value, as seen in figure 2-16B. This suggests that Dpt may play an
important role in the development of arthritis. Both Htra1 and Dpt may be involved in the
Ifi204 molecular pathway[97].
The Sequence of the Genes in BALB/c-/- and DBA/1-/From gene mapping and microarray data, the number of candidate genes were
narrowed. We focused on the Ifi cluster on chromosome 1 between 173,680,000 to
174,100,000 bp to identify the differences in Ifi202b, Ifi203, Ifi204, Ifi205, and Mndal
genes between BALB/c-/- and DBA/1-/- strains (Figure 2-17, Table 2-3). RNA sequencing
was used to reduce the genomic interval. Each gene was searched online and known each
of their expression levels in different tissues and how many transcripts they had. The
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Figure 2-16. Graphic gene network between Ifi204 and genes within the QTL
region and genes relevant to the immune system.
(A) Graphic gene network based on expression correlations. The 18 nodes in the graph
show the selected traits below. All nodes are displayed. The 14 edges between the nodes
are shown, filtered from the 153 total edges. (B) Graphic network based on literature
reports. The 18 nodes in the graph show the selected traits below. The 33 edges between
the nodes are shown, filtered from the 153 total edges and drawn as curves, showing
Pearson correlation coefficients greater than 0.35 or less than -0.35.
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Figure 2-17. Ifi200 cluster is located on chromosome 1 between in 173.7Mb and
174.1Mb.
The Ifi200 gene cluster is located on chromosome 1 in a genomic region of a QTL for
non-MHC arthritis. This is the same position for Ifi204, Mndal, Ifi203, Ifi202b, and
Ifi205 genes on chromosome 1.
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Table 2-3.

The Ifi202b, Ifi203, Ifi204, Ifi205, and Mndal genes ID.

Name

Transcript ID

bp

Protein

Translation ID

Biotype

CCDS

UniProt

Flags

Ifi202b-201

ENSMUST0000
0000266.8

1697

445aa

ENSMUSP0000
0000266

Protein
coding

CCDS35794

Q9R002

TSL:1GENCODE
basicAPPRIS P1

Ifi203-201

ENSMUST0000
0042228.14
ENSMUST0000
0081216.11
ENSMUST0000
0156895.7
ENSMUST0000
0123708.7
ENSMUST0000
0129829.7
ENSMUST0000
0128430.7
ENSMUST0000
0135331.7
ENSMUST0000
0140143.1
ENSMUST0000
0138143.7

3754

457aa

A0A0R4J0H6

409aa

CCDS35793

E9PUG6

3605

457aa

CCDS48453

A0A0R4J0H6

3482

409aa

CCDS35793

E9PUG6

3054

871aa

CCDS78754

E9QAN9

1884

No protein

-

-

TSL:1GENCODE
basicAPPRIS ALT2
TSL:1GENCODE
basicAPPRIS P3
TSL:1GENCODE
basicAPPRIS ALT2
TSL:1GENCODE
basicAPPRIS P3
TSL:1GENCODE
basicAPPRIS ALT2
TSL:1

658

No protein

-

-

-

TSL:3

444

No protein

-

-

-

TSL:3

2471

No protein

-

Protein
coding
Protein
coding
Protein
coding
Protein
coding
Protein
coding
Processed
transcript
Processed
transcript
Processed
transcript
Processed
transcript

CCDS48453

3610

ENSMUSP0000
0042071
ENSMUSP0000
0079976
ENSMUSP0000
0114221
ENSMUSP0000
0121480
ENSMUSP0000
0122424
-

-

-

TSL:1

ENSMUST0000
0111214.3
ENSMUST0000
0192414.1

2296

619aa

E9QKL6 P0DOV2

No protein

Protein
coding
Processed
transcript

CCDS35792

1659

ENSMUSP0000
0106845
-

-

-

TSL:5GENCODE
basicAPPRIS P1
TSL:1

Ifi203-202
Ifi203-209
Ifi203-203
Ifi203-205
Ifi203-204
Ifi203-206
Ifi203-208
Ifi203-207

Ifi204-201
Ifi204-202
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Table 2-3.

Continued.

Name

Transcript ID

bp

Protein

Translation ID Biotype

CCDS

UniProt

Flags

Ifi205-201

ENSMUST0000
0059226.6
ENSMUST0000
0192166.1

1613

404aa

Q8CGE8

No protein

Protein
coding
Retained
intron

CCDS15534

3274

ENSMUSP0000
0062409
-

-

-

TSL:1GENCODE
basicAPPRIS P1
TSL:1

ENSMUST0000
0188804.6
ENSMUST0000
0111210.8
ENSMUST0000
0186442.6
ENSMUST0000
0190651.3
ENSMUST0000
0190071.1

2026

538aa

D0QMC3

538aa

CCDS48452

D0QMC3

1646

485aa

-

A0A087WRA4

762

184aa

-

A0A087WQG9

931

129aa

-

A0A087WSH9

ENSMUST0000
0189501.6
ENSMUST0000
0220623.1
ENSMUST0000
0191500.6
ENSMUST0000
0189474.6
ENSMUST0000
0187636.1

860

No protein

-

-

-

TSL:5

512

No protein

-

-

-

TSL:3

367

No protein

-

-

-

TSL:3

1353

No protein

-

-

-

TSL:1

667

No protein

-

Protein
coding
Protein
coding
Protein
coding
Protein
coding
Nonsense
mediated
decay
Processed
transcript
Processed
transcript
Processed
transcript
Retained
intron
Retained
intron

CCDS48452

1907

ENSMUSP0000
0140610
ENSMUSP0000
0106841
ENSMUSP0000
0140539
ENSMUSP0000
0140191
ENSMUSP0000
0141055

-

-

TSL:3

Ifi205-202

Mndal-204
Mndal-201
Mndal-202
Mndal-208
Mndal-207
Mndal-206
Mndal-210
Mndal-209
Mndal-205
Mndal-203
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TSL:1GENCODE
basicAPPRIS P2
TSL:1GENCODE
basicAPPRIS P2
TSL:5GENCODE
basicAPPRIS ALT2
CDS 3'
incompleteTSL:5
CDS 5'
incompleteTSL:5

Ifi202b gene had one transcript; the size of the gene was 1659 bp and the protein size was
445 aa. It had one consensus CDS, CCDS35794. Ifi203 had nine transcripts. All of them
had different gene sizes, but only five of them could encode proteins. The Ifi203-201
gene transcript size was 3754 bp and the protein size was 445 aa; the Ifi203-202 gene
transcript size was 3610 bp and the protein size was 409 aa; the Ifi203-209 gene
transcript size was 3605 bps and the protein size was 457 aa; the Ifi203-203 gene
transcript size was 3482 bp and the protein size was 409 aa; the Ifi203-205 transcript size
was 3054 bp and the protein size was 871 aa. These five transcripts had CCDSes and the
rest of the four transcripts did not encode proteins. The Ifi205 gene had two transcripts.
Only the Ifi205-201 transcript could be translated to a protein (404 aa) and the gene size
was 2296 bp. The Mndal gene had 10 transcripts, but only 5 could translate to protein.
The Mndal-204 transcript size was 2026 bp and the protein size was 538 aa; the Mndal201 transcript size was 1907 bp and the protein size was 538 aa; the Mndal-202 transcript
size was 1646 bp and the protein size was 485 aa; the Mndal-208 transcript size was 762
bp and the protein size was 184 aa; the Mndal-207 transcript size was 931 bp and the
protein size was 129 aa. The rest of the transcripts could not translate proteins. Ifi204 had
two transcripts, but only one could translate a protein. The Ifi204-201 gene transcript was
2296 bp and the protein size was 619 aa. Its consensus CDS ID was CCDS35792 (Figure
2-18). Ifi204-201 gene was sequenced and found several different polymorphisms
between BALB/c-/- and DBA/1-/-. At 292 bp and 293 bp, DBA/1-/- was AA and BALB/c-/was TG; at 197 bp, DBA/1-/- was G and BALB/c-/- was C; at 190 bp DBA/1-/- was T and
BALB/c-/- was G. The Ifi 204 protein structure changed between BALB/c-/- and DBA/1-/(Figure 2-19). The change from AA to TG changed the amino acid from lysine to
methionine. The T to C change changed the amino acid from tyrosine to histidine. The G
to C change made the amino acid change from serine to threonine. The fourth
polymorphism amino acid change could not be determined because the nucleotide
sequence was unclear. The Ifi 204 protein structure is likely to be different as encoded by
BALB/c-/- versus DBA/1-/- because of these amino acid changes.
The Ifi204 Expression Levels in Different Strains
Ifi204 gene expression levels were obtained from 4-month old DBA/1-/-, DBA.B1 , BALB.D-1-/-, and BALB/c-/-, DBA/1 wild type and BALB/c wild type male and
female mice (Figure 2-20). In both DBA/1 and BALB/c wild type mice, the Ifi204
expression levels of females were lower than that observed in males. In DBA/1-/- and
BALB/c-/- strains, there were contrasting expression levels among each gender. In the
DBA/1-/- strain, the expression levels in females were higher than that of males, but male
expression levels were higher than that of females in the BALB/c-/- strain. In the congenic
strains, the expression levels in males were higher than that observed in females in the
DBA.B-1-/- strain, and females were found to have higher expression than males in the
BALB.D-1-/- strain. Between the two congenic strains, males and females did not have
any significant difference, so we could not use these data for analysis. The data from realtime PCR and microarray had differences indicating that the two experiments used
different loci to test. In the DBA/1 background, there were contrasting expression levels
within each gender between wild type and IL-1ra knockout mice, but expression levels
-/-
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Figure 2-18. Ifi204 gene sequencing and designed primers on cDNA.
Eight pairs of primers are designed in Ifi204. Each color represents a pair of primers. The
primers overlapped each other, so there is no missing nucleotide between the first and last
primer when we sequence the Ifi204-containing sample.
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Figure 2-19. BALB/c-/- and DBA/1-/- have multiple polymorphisms on Ifi204 gene
sequencing.
The Ifi204 gene sequence in DBA/1-/- strain is shown on the top, and the bottom
representation is the BALB/c-/- strain. Comparing the sequences in these two strains, there
are several polymorphisms on the gene, causing the protein structure to be changed. (A)
At 292 bp and 293 bp, DBA/1-/- was AA and BALB/c-/- was TG, the amino acid changed
from Lys to Met; (B) at 190 bp DBA/1-/- was T and BALB/c-/- was C, the amino acid
changed from Tyr to His; (C) at 197 bp, DBA/1-/- was G and BALB/c-/- was C, the amino
acid changed from Ser to Thr.
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Figure 2-20. Ifi204 gene expression levels in both genders of each strain.
Ifi204 gene expression levels of 4-month old male and female DBA/1-/-, DBA.B-1-/-,
BALB.D-1-/-, BALB/c-/-, DBA/1 wild type, and BALB/c wild type mice expression levels
were measured from spleen tissue. (n=3). (* means p > 0.05) (A) Ifi204 gene expression
levels in DBA/1 background of both genders. The strains are shown below the horizontal
axis. Numbers to the left of the vertical axis are the ratios of relative expression. In
DBA/1 and DBA.B-1-/- strains, female gene expression is lower than that of male. In
DBA-/- strain, female gene expression is higher than that of male. (B) Ifi204 gene
expression levels in BALB/c background of both genders. The strains are shown below
the horizontal axis. Numbers to the left of the vertical axis are the ratios of relative
expression. In BALB/c and BALB/c-/- strains, female gene expression is lower than that
of male. In BALB.D-1-/- strain, female gene expression higher than that of male.
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were the same within the same gender in the BALB/c background. This is likely a result
of differential gender effects of the IL-1ra knockout in the different mice strains studied.
Foxp3+ Regulatory T Cells in Each Strain
Flow cytometry was used to determine the numbers, frequencies, and phenotypes
for specific types of lymphocytes. The percentage of lymphocytes expressing CD3, CD4,
CD8, CD25, and Foxp3 were compared for each strain. CD19 and CD3 were used to
analyze the concentration of B cells and T cells. In the BALB/c-/- strain, the B cells were
45% and T cells were 36% of total lymphocytes. In the DBA/1-/- strain, the B cells were
62.9% and T cells were 24.7% of total lymphocytes. The congenic BALB.D-1-/- strain
had 43.2% B cells and 44.9% T cells of total lymphocyte. The T cells in the BALB/c-/strain and the BALB.D-1-/- strain had a higher percentage than did the DBA/1-/-strain, and
the B cells in the BALB/c-/- strain and the BALB.D-1-/- strain had a lower percentage than
did the DBA/1-/- strain. For T cell subsets, CD4 and CD8 markers were analyzed.
Cytotoxic (CD8+) T cells were 26.4% and helper (CD4+) T cells were 64.8% in the
BALB/c-/- strain, cytotoxic T cells were 24.0% and helper T cells were 63.5% in the
DBA/1-/- strain, and cytotoxic T cells were 22.4% and helper T cells were 71% in the
BALB.D-1-/- strain. Cytotoxic T cells and helper T cells had similar percentages in the
three strains. Treg cell percentages in BALB/c-/-, DBA/1-/-, and BALB.D-1-/- were 25.7%,
37.6%, and 26.4%, respectively, in lymphocytes. The DBA/1-/- strain had a higher
percentage than the other two strains. The DBA/1-/- strain was arthritis-resistant and the
BALB/c-/- and BALB.D-1-/- strains were susceptible to arthritis (Figure 2-21).
The Effect of Arthritis on the Ankle Joint Area
SAD is observed in mouse ankle joints. This conclusion was based on the
previous observation that changing the genotype results in a different phenotype in the
ankle joint area in each strain. The ankle joint’s degree of severity in arthritis presentation
is most prevalent when the mice are growing. We scored and calculated the four limbs,
following the scale and the data given above. The severity of swelling and redness in the
ankle joint of hind legs was more serious in BALB/c-/- than found in DBA/1-/-.
Inflammation affects the cartilage and synovium. Ankle joints will lose function when the
synovial tissue is eroding. The inflammation can also affect the joint bones and result in
bone erosion. μCT is the best tool for testing our hypothesis. As Figure 2-22 shows, the
DBA/1-/- strain did not have arthritis as shown by the very smooth bone surface. In the
BALB/c-/- strain, the bone surface is obviously rough. We enlarged the ankle joint apart
from the whole leg so that we could display the difference between the two strains more
clearly. The whole bone volume and bone mineral density were measured for both the
males and females in the four strains. In whole bone volume, males were slightly greater
than that observed in females, but they were similar among each strain. We believed that
arthritis could not change whole bone volume. In bone mineral density, males were
higher than females in all strains. The bone mineral density in the DBA/1-/- strain was
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Figure 2-21. Analysis of foxp3 in lymphocyte cells of BALB. D-1-/- compare with
BALB/c-/- and DBA/1-/-.
Cells were harvested at 4 months. Representative ﬂow cytometry histograms show CD3,
CD19, CD4, CD8, CD25, and foxp3 expression on splenocytes from BALB/c-/-, DBA/1-/-,
and BALB.D-1-/- female mice (n=3). (A) Percentages of T cells and B cells in each strain.
In the BALB/c-/- strain, the B cells were 45% and T cells were 36% of total lymphocytes.
In the DBA/1-/- strain, the B cells were 62.9% and T cells were 24.7% of total
lymphocytes. (B) Percentages of Helper T cells and cytotoxic T cells in the three strains.
Cytotoxic T cells were 26.4% and helper T cells were 64.8% in the BALB/c-/- strain,
cytotoxic T cells were 24.0% and helper T cells were 63.5% in the DBA/1-/- strain, and
cytotoxic T cells were 22.4% and helper T cells were 71% in the BALB.D-1-/- strain. (C)
Percentages of T regulator cells (Tregs) in the three strains. Treg cell percentages in
BALB/c-/-, DBA/1-/-, and BALB.D-1-/- were 25.7%, 37.6%, and 26.4%, respectively, in
lymphocytes.
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Figure 2-22. The structure of ankle joint bones shows in BALB/c-/-, DBA-/-,
BALB.D-1-/-, and DBA.B-1-/-.
(A) Images from μCT show that the DBA/1-/- mice have very smooth bone surfaces and
the BALB/c-/- mice have obvious irregularities on the surface of the ankle joint areas. (B)
Comparison of whole bone volume differences between BALB/c-/-, DBA-/-, BALB.D-1-/-,
and DBA.B-1-/- mice. The strains are shown below the horizontal axis. Numbers to the
left of the vertical axis are the bone volume in cubic millimeters. In all four strains, the
male expresses a slightly higher volume than the female, but there are no significant
differences between strains. (C) Comparison of bone mineral density differences in
BALB/c-/-, DBA-/-, BALB.D-1-/-, and DBA.B-1-/- mice. The strains are shown below the
horizontal axis. Numbers to the left of the vertical axis are bone density in mgHA/mm3.
Males have higher bone mineral density than females in all four strains. DBA/1-/- has
higher bone mineral density than that of BALB/c-/-.
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higher than BALB/c-/- in both genders. Arthritis could erode the bone and decrease the
bone density. The two congenic strains, DBA.B-1-/- and BALB.D-1-/-, were scored
between the two parental strains’ observed scores.
Discussion
Using an F2 mouse population from a resistant strain, DBA/1-/-, and a strain
susceptible to spontaneous arthritis, BALB/c-/-, we were able to study spontaneous
arthritis in the absence of IL-1ra QTLs-regulated mapping. From the different QTL
location numbers, we discovered spontaneous arthritis is controlled by many genetic
factors. The QTLs on chromosome 1 had been found to have a major genetic effect on
spontaneous arthritis. Through the QTLs, the region can be narrowed down, and we can
thereby reduce the work needed to find the candidate genes. The QTLs on chromosome 1
were very useful in our study. The candidate genes were confirmed in this region, but the
genomic region of the QTL was still at too large of a range – more than 300 genes were
on this region. Different gene expression levels were identified between the congenic and
parental mice on this region. From the online database, the gene function and correlation
can be searched. We obtained a list of candidate genes through bioinformatics, gene
expression profiles, and molecular pathway analysis.
IL-1ra has been linked to many diseases: respiratory diseases, aneurysm
formation, and periostitis, among others. There were no diseases found in BALB/c-/-,
DBA/1-/-, and the two congenic mice strains. Diseases might appear in a small number of
mice, but it was not a common phenomenon. CIA involves late steps in the molecular
pathway, but IL-1ra is involved in earlier steps. Because the IL-1ra-deficient arthritis was
heritable and spontaneous, the BALB/c-/- and DBA/1-/- genomic background were very
useful for understanding the QTLs. The homozygous disease mouse model is a useful
tool for studying diseases falling under a uniform genomic background, but many of
these studies result in failed human trials. The use of multiple animal strains can help us
to understand the range and variability in disease regulation of different genes or genetic
loci of interest. Parental strains and their congenic mice could enhance our study of the
molecular mechanism, and so provide a useful tool for searching the candidate genes.
The QTL region conferring susceptibility to spontaneous arthritis is on
chromosome 1 and functions in both directions. The two congenic mice BALB.D-1-/- and
DBA.B-1-/- were created from the DBA/1-/- and BALB/c-/- parental strains. A DNA
fragment covering the QTL loci was transferred from the DBA/1-/- strain onto the
BALB/c-/- strain background to build the BALB.D-1-/- congenic strain. The fragment of
DNA from the same QTL loci from BALB/c-/- strain was transferred onto the DBA/1-/strain to build the DBA.B-1-/- congenic strain. In the BALB.D-1-/- congenic strain, the
onset of the disease was delayed and it was less severe than found in the BALB/c-/parental strain. The DBA.B-1-/- congenic strain showed an increased possibility of
suffering from arthritis in comparison to DBA/1-/-. The two congenic strains can be used
to confirm the function of the QTL and help us to understand the sequence of the
genomic region of the QTL. Most studies only transfer the fragment in one direction,
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transferring one piece of genomic DNA from one strain to another strain, but not
transferring the section of DNA from the same location on the second strain to the first.
In our study, we exchanged DNA fragments from both strains. They were useful models
for studying the interaction of the QTL region and the whole genome in the congenic
strains. The genomic DNA from a QTL loci in the two congenic strains can either
increase or decrease the susceptibility to arthritis in comparison to their parental strains.
The exchange of the DNA fragments in the congenic strains can help inform our
understanding of the molecular mechanisms of the genes in the QTL region. The data
from the four strains prove that the genotype and molecular pathways interact. By using
the two congenic strains, we can confirm the function of the QTL region and clearly
define the genes that regulate the susceptibility to spontaneous arthritis.
The phenotype of the mouse strains was studied by scoring the ankle joints at
different periods throughout growth and by imaging the bone with a μCT after collection.
The two parent strains were on opposite ends of the scoring spectrum, as BALB/c-/showed signs of severe arthritis early, and DBA/1-/- showed no signs. The congenic
strains had less extreme results, with BALB.D-1-/- having less severe joint swelling and
redness than its parent strain, and DBA.B-1-/- having more than its parent. The male
BALB/c-/- and BALB.D-1-/- mice had higher severity than the females. A study using
mouse models to investigate osteoarthritis found that sex hormones play a significant role
in the progression of arthritis in mice, with it being more severe in males. This study
concluded that estrogen plays a protective role in osteoarthritis and may explain why
males had it with greater severity. They did not establish a correlation between
testosterone and osteoarthritis. The role of sex hormones could also be applicable to SAD
and may explain why the severity progressed quicker in the males than in the females.
Arthritis is affected by genetics and the environment. This means that although the
DBA/1-/- strain does not have the genetic background to cause arthritis, it is susceptible to
the disease because of its environment. However, the severity of arthritis would be much
lower than the genetically influenced disease. The substantial influence genetics has on
arthritis is demonstrated by the incidence rate in Figure 2-4. BALB.D-1-/- has delayed
incidence and severity compared to its parent BALB/c-/- because of the transferred
genomic region from DBA/1-/-. DBA.B-1-/- has a higher chance of getting the disease,
and at an earlier age, in comparison to its parent DBA/1-/- as a result of the genomic
region from BALB/c-/-. Swelling and inflammation are evident in the images of the
BALB/c-/- and BALB.D-1-/- mice in Figure 2-3. Using congenic strains allows us to
prove that the genes affecting arthritis are found in the region that we predicted. As
discussed above, transferring the genomic pieces from DBA/1-/- and BALB/c-/- to the
other strain affects the incidence and severity of arthritis; allowing us to conclude that the
candidate gene(s) are in this region. When watching the affected mice, it was obvious that
they walked slower and more cautiously so as to not put pressure on their hind legs. The
study indicated erosion of the soft tissue and synovium as a result of the inflammation
from arthritis, and after collection, it was found that the bones of the arthritic mice have
irregular surfaces, compared to the smooth surfaces of the healthy mice. The whole bone
volume did not show any major differences between the four strains; however, the bone
mineral density showed differences between BALB/c-/- and DBA/1-/- and between
genders. This indicates that arthritis decreases the bone mineral density. Besides being a
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direct effect of arthritis, the bone mineral density may decrease as a result of physical
inactivity due to pain from joint damage. Physical inactivity can cause a decrease in bone
mineral density because of a decrease in muscle strength that subsequently leads to less
loading of the bone. Studies have shown that bone loss in rheumatoid arthritis is a direct
result of the disease and is most prominent in areas surrounding the affected joints. The
severe erosion seen in Figure 2-22A is likely a result of these bones surrounding the
affected ankle joints. The tissue weights of the strains were similar when we collected
them at the same age. Normally, autoimmune system diseases like arthritis do not affect
the weight of organs because it is localized.
In our microarray data, a high correlation (R=0.9895) of gene expression was
found between the two congenic strains. Since the expression levels between the strains
are mostly the same, it allows us to identify the differences that could explain the genes’
varying susceptibility to SAD. The similarities are also found between the parents and the
congenic strains. As Figure 2-5 shows, the smallest correlation is still relatively high
(0.97), meaning we can compare the parent and congenic strains to identify differences
that could cause either a resistance or a susceptibility to arthritis. Using two congenic
strains allowed us to compare them to the other four strains (DBA/1-/-, BALB/c-/-, DBA/1
wild type, and BALB/c wild type) and narrow down the possible candidate genes by
examining overlapping upregulated genes between the comparison genes.
The function of the T-cell receptor beta chain and the Ifi cluster genes in SAD
susceptibility were confirmed by their expression levels in the BALB.D-1-/- strain. The
decreased expression levels of these genes in BALB.D-1-/-, in comparison to BALB/c-/-,
resulted in an increased resistance to SAD. In the strains that are resistant to SAD, DBA
wild type and DBA/1-/-, the expression levels of these genes were similar and were also
lower than found in the BALB/c wild type and BALB/c-/- strains, which are susceptible to
SAD. BALB/c-/- and BALB.D-1-/- had very few genes with differences in up- or
downregulation because most of the genes are from the BALB/c-/- background. This is
also true for the comparison between DBA.B-1-/- and DBA/1-/-. The congenic strains
compared to the donor allele strains showed many differences in the up- and
downregulated genes, since the majority of the congenic strains’ genes came from the
background. When comparing the congenic strains to their respective donor strains and
the wild type of the donor strain, the congenic strains had fewer differences in
comparison with the donor strain. All of the wild type strains had more differences in upand downregulated genes in comparison with the congenic strains than the IL-1ra
deficient strains showed, because the congenic strains were also IL-1ra deficient. The
data showed an Ifi200 cluster that contained candidate genes for SAD resistance in the
BALB.D-1-/- strain. The Ifi200 cluster genes between BALB.D-1-/- and BALB/c-/- were
expressed differentially and located in the transferred genomic fragment in the BALB.D1-/- strain. The genes were located on chromosome 1 from D1Mit110 to D1Mit209. The
microarray data displays differences between the two strains. The Ifi family genes may
not have the greatest difference between the strains, but from our data and that of other
studies, there is a large fold change, and therefore the Ifi200 cluster contained candidate
genes for SAD resistance. It has been published that Ifi proteins are immune suppressors.
For example, Ifi202b, Ifi203, Ifi204, Ifi205, and Mndal are known as interferon-inducible
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lupus susceptibility genes[146]. Since we believed that the Ifi200 gene family plays an
important role in arthritis, the number of transcripts per gene and the protein size of each
transcript were important to use as experimental search parameters.
To choose a gene to focus on within the Ifi200 family, we needed to compare the
relative expression levels of the family of genes made up by the congenic strains and
their parents. We hypothesized that the Ifi200 gene family influences the inflammation
found in arthritis, so searching the genes within this family, that had higher expression in
the arthritis susceptible strains, is a productive strategy. By comparing the congenic strain
to its parent and to the donor allele strain, we were able to determine which genes were
different in the DNA region of interest between the arthritis susceptible strain and the
resistant strain. Since BALB.D-1-/- has the DBA/1-/- DNA region, it would not be
expected to have different gene expression levels than DBA/1-/-, but we can examine the
differences between it and BALB/c-/- to find possible candidate genes. Ifi203, Ifi204, and
Ifi205 had negative differential expression scores between these two strains, thus we
focused on them as the possible candidate genes. Ifi202b did not have the positive
correlation that the other Ifi family genes had. A comparison between DBA.B-1-/- and its
parent strain and donor allele strain should also show differences similar to the BALB.D1-/- comparisons. From the narrowed results from the BALB.D-1-/- comparisons, the
differential expression scores were identified for Ifi205 and Ifi204 in DBA.B-1-/-, DBA/1
wild type, and DBA/1-/-. Expression levels of the Ifi family genes between the congenic
strain and its background strain were also determined. The candidate gene that is
positively correlated with the susceptibility of arthritis should be higher in DBA.B-1-/than in DBA/1-/- and lower in BALB.D-1-/- than in BALB/c-/-. Data from Ifi203, Ifi204,
and Ifi205 all agreed with this line of prediction. Ifi202b did not have a positive
correlation. Ifi204 had the highest overall expression in the arthritis susceptible strains,
hence we chose to focus on this one as the most favorable candidate gene.
Taken together, our data support the current evidence that Ifi204 is the candidate
gene obtained for the regulation of susceptibility to SAD in mice. There are many aspects
of the experimental evidence supporting our conclusion. Our data indicated that
expression levels of Ifi204 varied inversely with the resistance to SAD in the congenic
strain with the BALB/c-/- background; additionally, the expression levels of Ifi204 also
varied inversely with the resistance to SAD in the congenic strain DBA.B-1-/-.
Furthermore, the human homolog to mouse Ifi204, IFI16, has recently been linked to
arthritis, and the expression level of Ifi204 is the only gene in the Ifi200 cluster which
was found to be at a detectable or functional level. Finally, the Ifi200 cluster genes are
the only group of genes relevant to SAD within the QTL region, which showed
differential expression. This study will significantly enhance our understanding of the
roles of the Ifi204 gene in inflammatory diseases, because the role of the Ifi204 gene in
mice was recently found to be very similar to its human homolog IFI16, which is linked
to arthritis, as noted above[97].
The Ifi200 family is composed of interferon-activated genes, and thus its role in
infection and innate immune responses has been studied. Flow cytometry was used to
examine if the genes in the Ifi family interact with the T-cell receptor beta chain family to
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downregulate SAD. The possible interaction between these two families of genes was of
interest because the T-cell receptor beta chain family is known to a have a role in
controlling susceptibility to arthritis. Flow cytometry results in Figure 2-21 show that the
arthritic mice (BALB/c-/- and BALB.D-1-/-) have higher percentages of T cells than does
DBA1-/-, but lower percentages of cells expressing FoxP3. FoxP3 is a transcription factor
that helps regulate immune responses by activating or repressing anti-inflammatory
genes. This explains why the strains with severe inflammation have lower levels of
FoxP3, but higher levels of T-cells than the strain resistant to arthritis. Within the smaller
percentage of T cells in the DBA1-/- strain, there is a high percentage of Treg cells. FoxP3
helps Treg cells to suppress immune responses by a positive feedback mechanism.
DBA1-/- would be expected to have a high percentage of Treg cells and FoxP3, because
its phenotype does not present with the inflammation that coincides with immune
responses.
Our study again emphasized the power of whole genome analysis, as well as the
importance of quality and accuracy in microarray analysis. Because the microarray chip
contains more than 30,000 probes of mouse genes, any error in the technique could create
a large number of genes with false positive differential expressions. The large number of
differentially expressed genes between DBA.B-1-/-, BALB.D-1-/-, and the other three
parental strains suggested that the small number of differentially expressed genes
between DBA.B-1-/- and DBA/1-/- are most likely to be the true differentially expressed
genes. Furthermore, the precise agreement on the expression level of genes in the Ifi
cluster between DBA.B-1-/- versus DBA/1-/- and DBA.B-1-/- versus DBA/1 wild type
confirms the accuracy of this analysis.
One should note that both LOC638301 and LOC100044430 were withdrawn,
most likely due to the inaccuracy of their sequences. However, their probes on the
Illumina mouse-6 v1.1 were highly similar to that of Ifi204 and Ifi205. Because of the
high similarity to the sequences of Ifi family genes, their probes were most likely to
detect the expression of Ifi204 and Ifi205, with certain mismatches to other genes.
Because differential expression of the Ifi family in our study was not exclusively based
on these two probes, we felt that the data were truly representative in terms of the
connection between the expression level of Ifi family genes and spontaneous arthritis
disease. Zhang et al. indicated in their study that Mndal was absent from DBA/2. With
the close genome background between DBA/2 and DBA/1, one would assume that Mndal
in the DBA/1 strain is also absent[147]. Considering the similarity among genes in the
Ifi200 family cluster, we speculate that the increased level of the expression level of
Mndal, in this case, could reflect (1) a partial rather than complete deletion, or (2) crossreactivity to other genes in the Ifi family cluster. Thus, these probes represent probes for
the Ifi200 family, and we detect their expression levels at the whole family level, rather
than at the level of individual genes in the cluster[97].
Using real-time PCR to test the expression level of Ifi204 between BALB/c-/-,
DBA/1-/-, BALB.D-1-/-, DBA/1-/-, BALB/c wild type and DBA/1 wild type, there is a
noticeable difference between Ifi204 gene expression level in DBA/1-/- and BALB/c-/strains, but the variation among the sexes within each strain is unexplainable at this
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moment. There is a definite relationship between Ifi204 expression and arthritis, as seen
in the comparison between the congenic strains and their parents. DBA/1-/- had lower
expression levels of Ifi204 than its congenic strain DBA/1-/-, and the congenic strain
BALB.D-1-/- had lower expression levels than its parent BALB/c-/-. This is to be
expected if Ifi204 plays a large role in SAD, because the DBA congenic strain had
arthritis while DBA/1-/- did not, and BALB/c-/- had arthritis whereas the disease was
lessened in its congenic strain.
Ifi204 plays a regulatory role in SAD. We sequenced the Ifi204 gene in the
DBA/1-/- and BALB/c-/- strains. There were several nucleotide polymorphisms in the
coding region between the two parental strains. This not only made the expression levels
different, but also changed the protein structure between the two strains. Multiple
nucleotide changes can have substantial effects on the protein, as just one change in
nucleotide can change the amino acid and thus the secondary and tertiary structure of the
protein. 1)The nucleotide from AA to TG change caused the expressed amino acid to
change from lysine to methionine. This is an exchange of a hydrophilic side chain to a
hydrophobic one. Charged amino acids can form ionic bonds, whereas hydrophobic ones
cannot. 2)The T to C nucleotide swap changed the amino acid from tyrosine to histidine.
This changed a hydrophobic amino acid to a positively charged amino acid. The
introduction of a positively charged amino acid could disrupt hydrophobic interactions,
which was shown to severely impact the phenotype or raise susceptibility to disease.
3)The G to C change switched the amino acid from serine to threonine. This did not
cause a change in the amino acid’s charge. The changes in amino acids could have an
effect on the protein’s structure and/or function. A change from a charged to an
uncharged amino acid, and vice versa, will change the pH of the protein. The difference
in proteins may be an important factor in causing the resistance of DBA/1-/- mice and the
susceptibility of BALB/c-/- mice to SAD. Because of the way primers function
experimentally, we have the complete nucleotide sequence at the beginning for Ifi204.
This would not change the start position for transcription but could have an effect on the
promoter. We found there are several nucleotides that can cause the gene mutation.
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CHAPTER 3.

GENETIC STUDY OF HUMAN SCLERODERMA USING THE
TIGHT SKIN MOUSE MODEL
Introduction

Scleroderma is a connective tissue disease characterized by hardening and
thickening of the skin and multiple other organs caused by an accumulation of collagen.
When the condition affects the internal organs, it is called systemic scleroderma, diffuse
scleroderma or systemic sclerosis. The disease is mainly divided into the following two
categories, localized scleroderma (morphea) and systemic sclerosis (SSc)[148-150].
Localized scleroderma can be further divided into subgroups depending on the shape and
distribution of the skin lesions. These subgroups are teardrop-shaped scleroderma,
scalded scleroderma, ribbon scleroderma, and generalized scleroderma. Localized
scleroderma only affects the skin of the face, hands, and feet. Scleroderma is an
autoimmune disorder, characterized by vascular alterations, production of antinuclear
antibodies (ANAs)[151], and the excessive accumulation of extracellular matrix (ECM)
proteins (mostly collagen) in the skin and some other internal organs[152]. There are two
types of scleroderma: the extremities type and the diffuse type. The etiology and
pathogenesis are unknown, but it is related to genetic factors, infectious factors, abnormal
metabolism of connective tissue, vascular abnormalities, and immune abnormalities.
Systemic sclerosis is a prototypic idiopathic fibrosing disease[149]. Fibrosis is the
development of excess extracellular matrix in organs or tissues. It can occur as part of the
reparative process or can be idiopathic in origin. The abnormal deposition of ECM is
stored in the skin, lung, heart, and gastrointestinal tract[152, 153]. However, many of the
basic mechanisms of disease pathogenesis remain elusive. Therefore, there are few
effective therapies for preventing fibrosis. Mouse models are useful tools to determine
the pathogenesis of the human disease.
There are several animal models for studying scleroderma. There are individual
gene deficiencies or overexpression that cause the vasculopathy and lung fibrosis in SSc.
The genes include Fos-related antigen-2 (Fra2)[151], endothelin-1 (Edn1)[154, 155], and
Friend leukemia integration 1 transcription factor (Fli1)[156]. Besides the genetic
models, there are also non-genetic models of SSc[157], such as the bleomycin-induced
scleroderma model[158-160] that have been used to study the initiating events of fibrosis.
Two main genetic mouse models used to study the skin effects of SSc are the tight skin 1
(Tsk1/+) mouse and the tight skin 2 (Tsk2/+) mouse. Both mouse models are
heterozygotes because the homozygote is embryonic lethal, but these two types of mouse
models have different molecular mechanisms. There is a tandem duplication of the
fibrillin-1(Fbn1) gene in chromosome 2 of Tsk1/+[161]. The Tsk2/+ mutation mouse
model is an ENU-induced dominant mutation on chromosome 1. The cutaneous
phenotype is similar to the tight skin 1 (Tsk1/+) mutation. Blankenhorn’s group found the
candidate gene collagen type III alpha 1 chain (Col3a1) in 2015[162]. Col3a1 is located
on chromosome 1 between 45,311,538 and 45,349,706[163]. It only has one major
transcript that encodes proteins. Collagens are a big group of proteins; the collagen
proteins can enhance and support many tissues in the body[164, 165]. Col3a1 can be
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found in the skin, intestine, lung, and blood vessel wall. The data cannot support Col3a1
as the only cause of skin fibrosis, since there is no effect on the other organs[166, 167].
Col3a1 may not be the only gene that causes the disease.
Our hypothesis is that ENU caused single nucleotide mutations in one or more
genes in the Tsk2 locus interval that determines the disease phenotype. Using a
combination of high-throughput screening and a bioinformatics approach correlating
published data and our own data, we tested this hypothesis to identify the gene(s)
underlying the Tsk2/+ phenotype. Tsk2/+ is a mutation that first appeared in the offspring
of a male from the 101/H strain that had been administered the mutagenic agent,
ethylnitrosourea, in 1986[168, 169]. Now, the Tsk2/+ mutation mice are under the
C57BL/6 background. Tsk2/+ mice have many symptoms similar to the human disease;
the dermis is tight, the macromolecule deposition dysregulates in the dermal extracellular
matrix, and the autoimmune response is disordered. Collagen and extracellular matrix
deposition are increased in the dermis of Tsk2/+ mice[170]. The cutaneous phenotype is
present in the whole skin and is measured in the interscapular region. Type I and type III
collagen are synthesized by fibroblasts in the dermis and deposited in the extracellular
matrix. Increased collagen expression by dermal fibroblasts results in the fibrotic
condition of the ECM. This is a characteristic of many fibrotic diseases. We will use this
Tsk2/+ mouse model to study the genetic factors that regulate fibrosis in the dermis. The
location of the mutagenized genes is known; however, the molecular mechanism of the
genetic defect is unclear. The genes are located on chromosome 1 from 42.5 to 52.5
megabases (Mb)[169]. Microarray data can narrow the number of Tsk2/+ candidate
mutation genes in this region. The Fhl2 gene exhibited a high expression level in Tsk2/+
mice; this allowed us to concentrate our focus on this candidate gene. The full name of
Fhl2 is gene four and a half LIM domain 2. This gene can encode one of the proteins in
the four-and-a-half-LIM-only family[171]. Fhl2 is located on chromosome 1 from
43,123,074 to 43,196,984. This gene has 2 transcripts that can encode a protein and is
composed of six exons. The protein works as a regulator in the development and
differentiation of the cell, as well as in numerous signaling pathways[172-174]. This gene
is also connected to bone formation and bone mineral density. Our research goal is to find
a connection between this gene and skin.
Material and Methods
Mice
Tsk2/+ mice were crossed on the C57BL/6 (B6) background and obtained from
Dr. Arnold Postlethwaite (University of Tennessee Health Science Center, Memphis,
TN). The wild type C57BL/6J strain mice were purchased from the Jackson Laboratory.
Both strains of mice were housed at the animal facility in the Coleman Building,
University of Tennessee Health Science Center (UTHSC). The animal facility room
conditions were 12 hr light / 12 hr dark per day, the temperature was 22 ± 2 °C, and
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relative humidity was controlled between 30% to 60%. All animal experimental
procedures for this study followed the protocol set by the IACUC of UTHSC.
The tight skin disease phenotype in Tsk2/+ mice and B6 mice were bred in
standard microisolator cages. The mice had been measured for their body weight (g),
body length (cm), tail length (cm) and skin score (cm) when they were anesthetized, on
days 21, 28, 32, 35, 40, 42, 45, 49, 53, 56, 59, 63, 66, 70, 73, 80, 87, 94, and 101.
Genotyping
Ear pieces (about 2 mm2) of the 3-4-week-old Tsk2/+ mice were taken by using
sterilized ear punch (with anesthesia) the first time the mice were marked. The tissue was
immediately used for DNA extraction or frozen at -80°C. DNA was isolated by
“HotSHOT” genomic DNA preparation protocol. The ear pieces were put in 75 μl
Alkaline Lysis Reagent (25 mM NaOH: 0.2 mM EDTA, pH 12) incubated at 95°C for 10
min to 1 h, then 75 μl Neutralization Buffer (40 mM Tris-HCL, pH 5) was added. PCR
was used to genotype mice. Primers used: Col3a1-dna-T, forward primer:
5’CCCACAGATGAATTGGGAA; reverse primer 5’CAACAGACATGGCTTGCATT;
expected product size: 323 bp. Col3a1-dna-N, forward primer:
5’CCCACAGATGAATTGGGAT; reverse primer 5’CAACAGACATGGCTTGCATT;
expected product size: 323 bp (IDT, CA). mRNAs were also collected for rt-PCR to
distinguish between the Tsk2/+ and B6 mice. The rt-PCR primers were used forward
primer Col3a1-T-F: 5’ -ACGTAGATGAATTGGGAA- 3’ with reverse primer Col3a1T/N-R: 5’-ACGTAGATGAATTGGGAT- 3’ and forward primer Col3a1-T-N: 5’ACGTAGATGAATTGGGA- 3’ with same reverse primer Col3a1-T/N-R.
Collection of Mouse Tissues
Mice were collected at 4, 6, and 10 weeks of age and all tissues (heart, muscle,
liver, spleen, lung, kidney, and one piece of skin) were stored separately in 1.5 ml tubes
and immediately put on dry ice. One piece of skin was stored in RNAlater solution
(Thermo Fisher, CA) at 4°C until the skin completely absorbed the solution. After, all
mouse tissues were stored at -80°C for subsequent experiments.
RNA/DNA Isolation
RNA: A piece of tissue that had been stored in the -80°C freezer was cut on dry
ice before it melted. The tissue samples were put in 1 ml TRIzol and then the solution
was homogenized. 0.2 ml of chloroform per 1 ml of TRIzol sample was then added. After
being centrifuged, the top phase of the solution was moved to a new tube with 0.5 ml of
100% isopropanol. The mix solution was kept in a fridge for 40 min and then centrifuged
to produce the RNA pellet. Next, they were washed with 75% ethanol three times. Water
and sodium acetate:ethanol (4:96) was added to purify the RNA at -20°C overnight. The
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next morning, the RNA was washed and measured, the concentration was assessed by
nanodrop 2000 spectrophotometry (Thermo Scientific, CA). The RNA samples’ quality
was verified by agarose gel electrophoresis, which should have 3 bands (5S, 18S, and
28S). RNAs were stored at -80°C until the experiment.
DNA: DNA was extracted using the DNeasy Blood & Tissue Kit (Qiagen, CA).
The DNA samples’ integrity was also verified by agarose gel electrophoresis; most
fragments should be larger than 5 kb and have no distinct smear band. The concentration
and contamination were also measured by nanodrop 2000 spectrophotometry (Thermo
Scientific, CA). DNA samples were stored at -20°C until the experiment.
Microarray Procedure
The RNAs were isolated from B6 and Tsk2/+ mouse spleen samples. Three
individual RNA samples had been pooled as one group in each well. The SuperScript
Choice System (Invitrogen, CA) reverse transferred the RNA samples to cDNA, and then
we used Enzo® BioArray HighYield RNA transcript labeling kit to produce cRNA. The
cRNA samples were loaded on GeneChip mouse genome U74Av2 array (Affymetrix,
CA) and hybridized at 45°C overnight, following the manufacturer's protocol. The
genechip was washed and stained by Affymetrix Fluidics Station 400 and scanned by
Agilent GeneArray Scanner. The raw data were analyzed by MAS 5.0 software
(Affymetrix).
Semi-quantitative Rt-PCR
RNA samples were used to measure the gene expression of Col3a1 and Fhl2
between B6 and Tsk2/+. The expression levels were used to confirm the data from the
Microarray. The RNA samples were isolated from the skin, muscle, heart, kidney, liver,
and lung. Each RNA sample was tested for the expression levels separately. One-step
RT-PCR kit from Thermo scientific was used and we followed the manufacturer’s
protocol. Specific primers were designed by the Primer3 online service. The reaction was
performed in a total volume of 12.5 μL, the total RNA volume was 1 ng, and the volume
of the forward and reverse primers was 50 nM in the reaction. cDNA synthesis and predenaturation were performed in 1 cycle of 50°C for 30 min, and 95°C for 15 min. PCR
amplification was performed in 35 cycles at 94°C for 30 s, 60-54°C for 40 s, and 72°C
for 1 min. The final extension was 72°C for 5 min. The PCR products were analyzed on a
1.8% agarose gel.
Sequencing Analysis
All of the chromosomal regions of interest were sequenced. The exon, intron, and
promotor were identified between B6 and Tsk2/+ mice (Table 3-1). DNA or mRNA
samples were amplified to their PCR products. All of the PCR and rt-PCR products were
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Table 3-1.

The Fhl2 gene primer.

Name
Fhl2cd1(1417)
Fhl2cd1(1566)

Forward-Primer
cattaaagcaacccaatgaagc

Reverse-Primer
aggacaagtccttgcagtcg

Size(bp)
290

cagctcctgctgcactcc

gcagtcaaagcgttcagtca

298

Fhl2-CD1
Fhl2-CD2
Fhl2-CD3

attaaagcaacccaatgaagc
atggaatacaagggcagcag
aatggcacaacgactgcttt

ctgctgcccttgtattccat
gccgccttcaaatatccttt
aaggaagtcacaaagctgcaa

496
505
481

Fhl2-DNAx1
Fhl2-DNAx2
Fhl2-DNAx3
Fhl2-DNAx4
Fhl2-DNAx5
Fhl2-DNAx6
Fhl2-DNAx7
Fhl2-DNAx8

caaatggggacgtgcatag
ggtctgtggtagcgtcatca
tttccctgaaacttttgagca
gcttgtccacaggcaaatct
aggagccattgagagcagaa
agccacaggtccctccat
gtacagcgggctcaaacatt
cgcagagattcggatgtttt

gagctggggtcctgaggt
tctcctatcgccagaacctg
gcagctctgctctgctttgt
gcccagcactgaagtatcaa
caagagaacagatgcgcaag
agacgtccatgttgttccag
ggatcttgtccccactgaga
gagggagaaaagtcggtgct

452
451
451
456
436
400
442
461

Fh2-ax-1
Fh2-ax-2
Fh2-ax-3
Fh2-ax-4
Fh2-ax-5
Fh2-ax-6
Fh2-ax-7
Fh2-ax-8
Fh2-ax-9
Fh2-ax-10
Fh2-ax-11

gtgcagcagcatcagggta
ctgtgcctgcctttctatcc
aggagtgtggaacacccatc
ccaacagggaggcagtaaca
ctgtgcaccgactgctattc
tccacttaaaactcccaacca
gccctgctatgagaagcagt
ctggtttccactccgaaaac
actgcctgacctgcttctgt
tggaaaccagtccctcaaac
tcaagcacagtgtgtgggact

attcggctctcctatgctca
gcagtcaaagcgttcagtca
caagagagtaccgccctgag
agtgccgatccttgtaggac
aggggtaggggttgagacag
acaggtgaagcaggtctcgt
tgaagtcctggaagtgtcacc
tgctcccggtaagtaacacc
cccacctagctgtggtttgt
tgtactttgtgccacccaga
gcatttgcacatatacacattca

355
350
346
356
349
317
397
352
415
353
354

Fhl2-Fdna 1
Fhl2-Fdna 2
Fhl2-Fdna 3
Fhl2-Fdna 4
Fhl2-Fdna 5
Fhl2-Fdna 6
Fhl2-Fdna 7
Fhl2-Fdna 8

cagctgctacagctctctgc
cagagggagccaactgaatgt
agtcactacccaggccttc
ccaaggtggacagcacttct
tgactgcgtggcagttattc
atccctcaattgcaagatgg
cagcaaaacaaaacaaaacagg
tggagagatggctcagaggt

taagggaacccagcggact
tccagggctagttgctatgc
aatgaaccaaaccgatgacc
tatcctcatgcccaggaaag
gactggtgctcagcttcctc
cgtggtggaacctcagaact
ggagagtgagcaagctgagg
aagagtaacaaaacgccgattc

353
358
353
326
352
352
313
349
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cleaned with EXOSA-IT PCR CLEAN-UP PROTOCOL. 5 μl PCR or rt-PCR products
and 2 μl ExoSAP-IT mix were incubated at 37°C for 25 min followed by 80°C for 15
min. 3 μl cleaned DNA samples, 1 μl single primer, and 8 μl water was used for
sequencing. Samples were loaded on ABI Model 3130XL Genetic Analyzers (Thermo
Fisher Scientific, CA). The data were analyzed by Finch TV and ABI Sequence Scanning
Software.
Quantitative Real-Time PCR
The TaqMan Reverse Transcription Reagents (Roche, AG) were used to amplify
the individual samples, following the manufacturer’s instructions. The cDNA samples
were mixed with the TaqMan Universal PCR Master mix. TaqMan gene expression
assays containing FAM-labeled primer/probe sets specific for Fhl2(Mm00515778_m1)
and GAPDH(Mm03302249_g1) were obtained from Applied Biosystems. The real-time
PCR reactions were performed in a total reaction volume of 25 μL by using FastStart
TaqMan Probe Master (Roche) reagent, and results were analyzed using the ABI 7900
real-time PCR-detection system (Applied Biosystems). Relative expression was
normalized to 18S RNA and calibrated to the respective controls.
Western Blotting
Western blotting was used to determine Fhl2 expression level differences between
the normal control B6 mice and Tsk2/+ mutation mice. Protein from samples of the same
region of skin was isolated by using RIPA Lysis Buffer (Santa Cruz Biotechnology, TX).
The protein concentration was tested by nanodrop 2000 (Thermo Fisher, CA). All
samples were diluted by Sample Buffer, Laemmli 2x Concentrate (SIGMA, MO) to a
ratio of 1:1 and boiled at 95°C for 10 min. The gradient polyacrylamide gel that was used
contained 6% stacking gel on top and 10% the separating gel on bottom. The 6%
Stacking Gel: 2.9 ml ddH2O, 0.75 ml 40% Acrylamide, 1.25 ml 0.5 M Tris, pH 6.8, 50 μl
10% SDS, 50 μl 10% APS, and 5 μl TEMED. The 10% Separating Gel: 3.8 ml ddH2O, 2
ml 40% Acrylamide, 2 ml 1.5 M Tris, pH 8.8, 80 μl 10% SDS, 80 μl 10% APS, and 8 μl
TEMED. The samples in each well were loaded with 1x electrophoresis buffer (25 mM
Tris, 0.25 M glycine, 5 mM SDS), with 100 Volts, and were run for 1.5 hr. Proteins were
then transferred to polyvinylidene difluoride membranes (Millipore Sigma, MA) in a
transfer buffer containing 0.2 M glycine, 25 mM Tris, and 20% methanol, pH 8.3 at 4°C,
100V, for 1.25 hr. After transfer, membranes were blocked in 5% BSA in TBST buffer
(10 mM Tris and 0.9% NaCl, and 0.1% Tween20) for 2 hr at room temperature (RT).
After blocking, the membranes were washed with 1x TBST three times. Membranes had
been cut to a suitable size and then incubated with the selective antibody against Fhl2 (1st
antibody,1:2000) overnight at 4°C. On the second day, after washing the membranes
three times, the membranes were incubated in the 2nd antibody (1:5000; Abcam, UK) for
1 hr at RT. They were then washed three times, and the membranes were exposed on the
Classic Autoradiography film (MIDSCI, MO) for 5 min in the dark room. The Fhl2
protein was 32 kDa. The membranes were stripped with Restore Western Blot Stripping
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Buffer (Thermo, CA) and added GAPDH as a control for the protein quantity. ImageJ
software (NIH, Bethesda, MD, USA) was used to quantify protein expression levels.
Result
Mouse Phenotype
In the current study, the Tsk2/+ mutation and C57BL6/J B6 mice were bred in the
animal facility under the same conditions. Body size, body shape, and hair color were
similar between the Tsk2/+ and normal mice as compared with the naked eye. The only
significant difference between the Tsk2/+ mutation and B6 normal was the tightness of
the skin (Figure 3-1). The phenotype of tight skin in Tsk2/+ mice is physically evident
and can be felt upon pinching the skin of young mice as early as three weeks of age. The
Tsk2/+ mice and age-matched controls were evaluated by body length, tail length, body
weight, and skin score at several time points. The mice were measured on days 21, 28,
32, 35, 40, 42, 45, 49, 53, 56, 59, 63, 66, 70, 73, 80, 87, 94, 101. At these selected time
periods, the body length and the tail length of the male and female Tsk2/+ and B6 mice
did not show any distinct changes (Figure 3-2A, B). The males were heavier than the
females of all ages in both B6 and Tsk2/+. Within the same gender, the Tsk2/+ mice were
reported to weigh less than their normal B6 littermates (Figure 3-2C). Pictures were
taken at the 4 and 6-week time points; in the pictures, the interscapular skin was grasped
to measure the skin tightness. An obvious difference could be felt between the two
strains. In the photos, the tightness of the skin was marked with a red circle, and there are
different circle sizes between the B6 and Tsk2/+ mice. Measuring of the skin was done
by the same person to ensure that the same method and location of grabbing were used,
providing consistency for the data. The skin of the one and two-week-old mice is too
difficult to grasp because they are too small. According to the literature, the disease
phenotypes begin to show around three weeks. Both genders of Tsk2/+ and B6 have been
measured at all time points. The skin measurements have significant differences; the B6
skin can be grasped ~ 1.7cm, but the Tsk2/+ only can be grasped ~ 0.7cm (Figure 3-2D).
Verification of Tsk2/+ Mice
Four pairs of primers were used to identify the Tsk2/+ and normal mice by PCR
and rt-PCR. The pair of primers for PCR were Col3a1-dna-T and Col3a1-dna-N and the
primers for rt-PCR were Col3a1-T and Col3a1-N to confirm the Tsk2/+ and B6
genotypes (data not shown) using PCR. The mRNA samples were used to confirm that
the Col3a1 gene is the mutated gene. The mRNA samples 1-3 from 4wks-B6 skin and
samples 4-6 from 4wks-Tsk/2+ were amplified by rt-PCR using the Col3a1-T-F and
Col3a1-T/N-R pair of primers. Col3a1-T can amplify the 4wks-Tsk2/+ skin RNA, but
cannot amplify the 4wks-B6 skin RNA. Both of the Tsk2/+ and B6 skins’ RNA can be
amplified by Col3a1-N (Figure 3-3A, B). Both Tsk2/+ and B6 can be amplified by
Col3a1-N primers because Tsk2/+ is heterozygous. We compared the Col3a1 gene
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Figure 3-1. The phenotype of Tsk2/+ and B6 skin tightness when they are 4 and 6
weeks of age.
(A) Comparison of the body size, body shape and hair color between Tsk2/+ and B6
mice. (B, C) Comparing the difference in how much skin is able to be grasped at four
weeks old. (D, E) Comparing the difference in how much skin can be grasped at six
weeks old. (F, G) The skin score is measured using a ruler when skin is grasped on the
back. The body, tail shape, and hair from Tsk2/+ and B6 skin are similar. The
interscapular skin in Tsk2/+ is tighter than B6 mice at both 4 and 6 weeks.
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Figure 3-2. Comparison of body length, body weight, tail length, and skin
tightness score in male and female Tsk2/+ and B6 mice.
(A, B) The body length and tail length are compared between the Tsk2/+ and B6 mice in
both genders. The times (days) are shown below the horizontal axis. Numbers to the left
of the vertical axis are the lengths (cm). The body length increases for both strains until
about forty-five days, and then it stabilizes. The tail length of both strains increases
steadily throughout their lifetime. The Tsk2/+ and B6 body length and tail length of both
the males and females do not show obvious changes. (C) The body weight is compared
between the Tsk2/+ and B6 mice in both genders. The times (days) are shown below the
horizontal axis. Numbers to the left of the vertical axis are the weights (g). The Tsk2/+
mice were reported to weigh less than their normal B6 littermates in both genders. The
males of both strains weighed more than the females. The body weights of the two strains
steadily grow throughout their lifetime. D) The skinscore is compared between the
Tsk2/+ and B6 mice in both genders. The times (days) are shown below the horizontal
axis. Numbers to the left of the vertical axis are the lengths (cm). The skin score is stable
throughout the mice’s lifetime. The B6 skin can be grasped ~ 1.7cm, but the Tsk2/+ only
can be grasped ~ 0.7cm.

66

Figure 3-3. Identifying and comparing the Tsk2/+ and B6 by Col3a1 candidate
mutation gene and Col3a1 gene expression levels between Tsk2/+ and B6 tissues.
(A, B) Identifying the SNP between 4 weeks Tsk2/+ and B6 with skin mRNA. The
Col3a1-T can amplify the Tsk2/+, but cannot amplify the B6. Both Tsk2/+ and B6 can be
amplified by Col3a1-N. No. 1-3 are 4 weeks B6 skin mRNA samples and No. 4-6 are 4
weeks Tsk2/+ skin mRNA samples. (C) The Col3a1 gene expression levels compared
between Tsk2/+ and B6 mice in different tissues. There is no difference between Tsk2/+
and B6 mice in skin, heart, and kidney. No. 1-3 are 4 weeks B6 skin mRNA samples and
No. 4-6 are 4 weeks Tsk2/+ skin mRNA samples.

67

expression level between B6 and Tsk2/+ by primer Col3a1-12 (forward:
CGTAAGCACTGGTGGACAGA, reverse: TGGGGTTTCAGAGAGTTTGG; bp: 489)
in the skin, heart, and kidney tissues. There is no obvious difference between Tsk2/+ and
normal (Figure 3-3C).
Microarray Analysis of Tsk2/+ Mice
Tsk2/+ is under the B6 background, and there were a small number of genes
changing the expression levels. However, the expression levels of more than 99% of the
genes compared between these two mice are similar. In analyzing the expression levels of
genes in B6 and Tsk2/+, the expression levels of eighty-two probes were found to be
upregulated and 177 probes were downregulated in Tsk2/+ compare with B6 (Figure
3-4). A previous study found that the candidate gene is located on chromosome 1 from
42.5 to 52.5 Mb. In this region, there were twelve probes downregulated and four probes
upregulated. The downregulated probes were 1500015O10Rik, Kdelc1, Tgfbrap1, Eroc5,
Gulp1, Pou3f3, Gpr45, Uxs1, EG212225, Bivm, Tpp2, and Mrps9 and the upregulated
probes were Col3a1, Slc40a1, Slc39a10, and Fhl2.
Comparison of Two Genes
From the Ensemble database, the positions of Fhl2 and Col3a1 were both on
chromosome 1, Fhl2 was from 43,123,074 to 43,196,984 and Col3a1 was from
45,311,538 to 45,349,706 bp (Figure 3-5A). From the online gene expression database,
we searched the BioGPS website (http://biogps.org/#goto=welcome) and compared the
gene expression levels of Col3a1 and Fhl2 in most tissues and organs in mice (Figure 35B). Unfortunately, there is no skin or dermis expression on this list, but most major
organs and tissues could be found. Fhl2 gene expression in epidermis, muscle, heart,
kidney, liver, and lung is 11.0915±4.5248, 46.2905±3.489572, 21857.0475±6050.6809,
194.9005±27.0645, 15.6560±6.9381, and 54.7640±35.6580 and the Col3a1 gene
expression is 1434.9770±841.9238, 1280.4620±364.6521, 389.3040±167.1120,
26.5730±18.3918, 15.2225±8.9442, and 540.1390±101.6706 (Table 3-2). The Fhl2 gene
is highly expressed in the heart but is not as highly expressed in the other organs. There
are eight organs or tissues where the expression level of Col3a1 is more than 2000, but
the heart is the only organ with an expression level more than 2000 in Fhl2.
Transcript of the Genes
On the Ensemble online database, there were basic data for the Col3a1 and Fhl2
genes (Table 3-2). The Col3a1 gene had seven transcripts and Fhl2 gene had three
transcripts. For the Col3a1 gene, there were three transcripts, Col3a1-201, Col3a1-205,
and Col3a1-204, that encoded proteins, but only Col3a1-201 had a CCDS. For Fhl2, all
three transcripts Fhl2-201, Fhl-202, and Fhl2-203 code for proteins, but only Fhl2-201
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Figure 3-4. Up and down regulated genes and networks in Tsk2/+ mice in
comparison to that of B6 mice.
(A) Upregulated genes in Tsk2/+ mice compared with B6 wild type. The gene names are
shown above the horizontal axis. Numbers to the left of the vertical axis are the fold
changes. The expression levels of eighty-two probes are upregulated. (B) Downregulated
genes in Tsk2/+ mice compared with B6 wild type. The gene names are shown below the
horizontal axis. Numbers to the left of the vertical axis are the fold changes. The
expression levels of 177 probes are downregulated.
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Figure 3-5. Fhl2 and Col3a1 are located on chromosome 1 and they are expressed
in different tissues.
(A) Fhl2 and Col3a1 are located on chromosome 1. Genes have been marked by red
arrows. Fhl2 is located on chromosome 1 from 43,123,074 to 43,196,984 and Col3a1 on
chromosome 1 from 45,311,538 to 45,349,706 bp. (B) Col3a1 and Fhl2 have different
expression levels in different tissues or organs. The organ names are shown below the
horizontal axis. Numbers to the left of the vertical axis are the expression level units. The
Fhl2 gene expression is high in the heart, where the expression level is more than 21000,
but there are no more than 1500 in other organs. The Col3a1 is expressed more than 1000
in eight organs.
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Table 3-2.

The Fhl2 and Col3a1 gene expression levels in each tissue or organ.

Samples

Fhl2

Stdev.S

Col3a1

Stdev.S

NK_cells.1
RAW_264_7.1
T-cells_CD4+.1
T-cells_CD8+.1
T-cells_foxP3+.1
Adipose_brown.1
Adipose_white.1
Adrenal_gland.1
Amygdala.1
Bladder.1
Bone.1
Bone_marrow.1
Cerebellum.1
Cerebral_cortex.1
Cerebral_cortex_prefrontal.1
Ciliary_bodies.1
Common_myeloid_progenitor.1
Cornea.1
Dorsal_root_ganglia.1
Dorsal_striatum.1
Embryonic_stem_line_Bruce4_p13.1
Embryonic_stem_line_V26_2_p16.1
Epidermis.1
Eyecup.1
Follicular_B-cells.1
Heart.1
Hippocampus.1
Hypothalamus.1
Intestine_large.1
Intestine_small.1
Iris.1
Kidney.1
Lacrimal_gland.1
Lens.1
Liver.1
Lung.1
Lymph_nodes.1
MIMCD-3.1
Mammary_gland__lact.1
Microglia.1
Min6.1

149.8985
14.0245
14.0400
34.9440
19.7865
17.8120
39.0065
128.4775
157.6655
314.5495
75.1865
32.2440
11.0695
326.5605
388.4195
9.0995
23.1110
11.5340
25.1470
45.6030
101.0710
115.9515
11.0915
36.6610
20.0530
21857.0475
161.0325
59.6850
187.3630
289.4680
19.3375
194.9005
12.9745
43.1585
15.6560
54.7640
9.0635
911.8575
62.0655
17.5020
8.7460

7.2570
4.9179
0.5459
3.5652
3.2308
0.4384
8.6486
25.1285
3.7781
55.9597
15.6532
10.5203
2.3511
70.4611
83.9993
1.2268
5.2312
6.7854
6.6015
6.5535
22.5355
25.4495
4.5248
27.0949
6.9565
6050.6809
31.4754
18.4385
6.8038
62.9509
9.5622
27.0645
5.1074
36.3517
6.9381
35.6580
0.8407
63.0152
16.7789
0.0000
1.5401

5.4795
5.5145
5.8075
5.6920
4.9720
1573.9835
953.7960
43.4440
5.2995
4003.3750
320.3745
4.9880
5.6920
5.7255
5.5580
15.2210
5.8075
8.2780
125.7045
9.8780
5.4795
7.3240
1434.9770
210.4600
5.1365
389.3040
5.3640
5.3640
289.0980
209.2300
74.6680
26.5730
20.5510
4.9720
15.2225
540.1390
255.2065
5.5695
4538.4560
71.9650
25.5350

0.6272
0.6767
0.1633
0.0000
0.0905
810.9461
384.0452
9.0708
0.3019
566.4618
111.4351
0.1131
0.0000
0.0474
0.5162
4.2978
0.1633
3.3729
43.3520
6.8476
0.6272
2.3080
841.9238
19.5416
0.1421
167.1120
0.4639
0.4639
21.8652
104.5302
36.8912
18.3918
20.6871
0.0905
8.9442
101.6706
242.4238
0.1732
184.6129
93.7242
11.9473
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Table 3-2.

Continued.

Samples

Fhl2

Stdev.S

Col3a1

Stdev.S

Neuro2a.1
Nih_3T3.1
Nucleus_accumbens.1
Olfactory_bulb.1
Osteoclasts.1
Ovary.1
Pancreas.1
Pituitary.1
Placenta.1
Prostate.1
Retina.1
Retinal_pigment_epithelium.1
Salivary_gland.1
Skeletal_muscle.1
Spinal_cord.1
Spleen.1
Stem_cells__HSC.1
Stomach.1
Testis.1
Thymocyte_DP_CD4+CD8+.1
Umbilical_cord.1
Uterus.1

11.1510
1437.8815
27.0160
121.1285
7.4330
201.6885
32.3720
41.6095
808.1875
171.2190
10.3610
17.0395
38.5275
46.2905
33.4055
18.1760
17.2505
388.9085
70.7280
23.5500
823.8050
183.2825

4.6655
155.7070
4.8663
0.1054
0.3168
0.4646
21.4098
30.1178
52.2220
1.1087
3.5879
8.9626
26.7845
3.4896
4.5163
0.9532
1.7727
87.7640
15.3796
3.6656
236.2373
21.4911

4.9945
30.8070
5.8100
5.3640
5.4795
1626.7425
239.1720
5.8245
847.4510
206.6360
5.4345
5.6920
849.0865
1280.4620
5.6920
21.9085
5.5995
605.5300
15.3590
5.3275
27661.4400
3108.8535

0.1223
26.5123
0.1598
0.4639
0.6272
1414.1690
22.0349
0.1393
60.2130
19.3719
0.3642
0.0000
1135.8391
364.6521
0.0000
9.1945
0.1308
213.3200
6.0712
0.4122
2335.1692
594.1910
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and Fhl2-201 had CCDSs (they both have two). Thus, Fhl2 has two transcripts that
encode proteins (Table 3-3).
Fhl2 Transcripts in Different Tissues
Through the previous searching, there were two transcripts with CCDSs in the
Fhl2 gene. The Fhl2 gene was composed of 6 segments of exons. The first exons on Fhl2201 and Fhl2-202 were completely different, but the remaining five exons were the same.
These two transcripts had different promoters. Fhl2-201 was 1566 bp and Fhl2-202 was
1417 bp (Figure 3-6). Two transcripts were identified per the expression levels in
different tissues. The Fhl2-201 transcript was expressed in the skin and kidney, but not
expressed in the muscle, heart, liver, and lung. The Fhl2-202 transcript was expressed
only in the heart, but not in the skin, muscle, kidney, liver, or lungs (Figure 3-7).
Fhl2 Gene Expression in Different Tissues at Different Ages
Real-time PCR was used to determine the Fhl2 gene expression levels in different
tissues in 4, 6, and 10-week-old female mice. In the skin, the Fhl2 expression level from
Tsk2/+ mice was higher than that of B6 at all time points. At 4 and 6 weeks, the Fhl2
expression level in Tsk2/+ were around 1.5-fold over that of B6. At 10 weeks, Tsk2/+
expression level was 2.5-fold. The B6 mouse skin expression remained around 1-fold at
4, 6, and 10 weeks (Figure 3-8A). The expression of Tsk2/+ increased significantly at 10
weeks compared to 4 and 6 weeks. In muscle, Fhl2 expression levels in Tsk2/+ were
slightly higher than B6 at 4 and 6 weeks. In heart and lung, Fhl2 expression levels in
Tsk2/+ were slightly higher than B6 at 4, 6, and 10 weeks. In the kidney, Fhl2 expression
levels in Tsk2/+ were slightly higher than B6 at 4 and 6 weeks, but not at 10 weeks.
Tsk2/+ were twice as high at 4 weeks and were also 1.6-fold higher than B6 at the same
age (Figure 3-8B).
Sequencing the Fhl2 Gene
We searched for polymorphisms in the Fhl2 gene that would establish it as the
likely candidate gene. We employed mRNA sequencing to reduce the genomic interval
(Figure 3-9A). We also sequenced the captured genomic DNA (Figure 3-9B), promoter
(Figure 3-9C), and introns connecting to each exon (Figure 3-9D). We used the B6
genome sequence as the control group to analyze the polymorphisms within the interval
in the Tsk2/+. We read many kilobases in the Fhl2 gene and genomic interval. We
wanted to find a polymorphism that would cause an overexpression or degeneration as a
result of changes in the protein structure, or protein denaturation as a result of intron
changes. We have not yet found a polymorphism in the Fhl2 gene between B6 and
Tsk2/+ (Figure 3-9E). We will expand our search to regions farther away in future
studies.
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Table 3-3.

The Ifi202b, Ifi203, Ifi204, Ifi205, and Mndal genes ID.

Name

Transcript ID

bp

Protein

Translation ID Biotype

CCDS

UniProt

Flags

Col3a1-201

ENSMUST000
00087883.12
ENSMUST000
00186021.1
ENSMUST000
00185687.1
ENSMUST000
00189818.1
ENSMUST000
00129611.1
ENSMUST000
00123204.1
ENSMUST000
00190943.1

5564

1464aa

P08121 Q3TVI5

245aa

-

A0A087WPJ5

583

195aa

-

A0A087WPS3

1610

No protein

-

-

TSL:1GENCODE
basicAPPRIS P1
CDS 5' and 3'
incompleteTSL:3
CDS 5' and 3'
incompleteTSL:5
TSL:3

3159

No protein

-

-

-

TSL:2

570

No protein

-

-

-

TSL:3

431

No protein

-

Protein
coding
Protein
coding
Protein
coding
Processed
transcript
Retained
intron
Retained
intron
Retained
intron

CCDS35554

737

ENSMUSP000
00085192
ENSMUSP000
00139802
ENSMUSP000
00139894
-

-

-

TSL:2

ENSMUST000
00008280.13
ENSMUST000
00185893.1
ENSMUST000
00187357.1

1563

279aa

O70433 Q543D7

279aa

CCDS14922

O70433 Q543D7

344

21aa

Protein
coding
Protein
coding
Protein
coding

CCDS14922

1421

ENSMUSP000
00008280
ENSMUSP000
00141170
ENSMUSP000
00140420

-

A0A087WR06

TSL:1GENCODE
basicAPPRIS P1
TSL:1GENCODE
basicAPPRIS P1
CDS 3'
incompleteTSL:2

Col3a1-205
Col3a1-204
Col3a1-206
Col3a1-203
Col3a1-202
Col3a1-207

Fhl2-201
Fhl2-202
Fhl2-203
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Figure 3-6. There are two transcripts of the Fhl2 gene.
In the Fhl2 gene, there are 6 exons used to assemble the gene. The highlighted regions are
the first exons of each transcript. The first exon is different in the two transcripts, except
for the area in red, which is the same. The rest of the five exons are the same.
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Figure 3-7. Comparing transcripts Fhl2-201 and Fhl2-202 in different tissues.
Fhl2-201 and Fhl2-202 expression levels are compared in the skin, muscle, heart, kidney,
liver, and lung between B6 and Tsk2/+. No. 1-3 are 4 weeks female B6 skin mRNA
samples and No. 4-6 are 4 weeks female Tsk2/+ skin mRNA samples. (A) Fhl2-201 is
expressed in the skin and expression in Tsk2/+ is higher than B6. There is no Fhl2-202
expression in the skin. (B) In the muscle, there is no expression of either transcripts. (C)
Fhl2-202 is expressed in the heart. There is no Fhl2-201 expression in the heart. (D)
Fhl2-201 is expressed in the kidney, and expression is not different between Tsk2/+ and
B6. There is no Fhl2-202 expression in the kidney. (E) In the liver, there is no expression
of either transcripts. (F) In the liver, there is no expression of either transcripts.
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Figure 3-8. The Fhl2 gene expression in Tsk2/+ and B6 mice tissues at 4, 6, and 10
weeks.
(A) The Fhl2 gene expression levels in Tsk2/+ and B6 female skin at 4, 6, and 10 weeks.
The strains are shown below the horizontal axis. Numbers to the left of the vertical axis
are the ratio of relative expression. At 4 and 6 weeks, Tsk2/+ were around 1.5-fold more
than normal. At 10 weeks, the Tsk2/+ expression level was 2.5-fold more than normal.
(B) The Fhl2 gene expression level in Tsk2/+ and B6 female muscle, heart, kidney, and
lung at 4, 6, and 10 weeks. The strains are shown below the horizontal axis. Numbers to
the left of the vertical axis are the ratio of relative expression. In the muscle TSK, is
higher than B6 at 4 and 6 weeks. There is no overall difference between TSK and B6 in
the heart and lung. TSK is higher than B6 in the kidney.

77

Figure 3-9. Fhl2 gene sequencing and designed primers on mRNA, genomic DNA,
promoter and intron.
The pairs of primers were designed for sequencing the Fhl2 gene. Each color represents a
pair of primers. The primers overlapped each other, so there were no missing nucleotides.
(A) The mRNA of Fhl2; (B) the genomic DNA covered the Fhl2 gene; (C) the promoter
of the Fhl2; (D) the introns beside the Fhl2 exons. (E) The sequences of B6 and Tsk2/+.
The top sequence is B6, the bottom Tsk2/+.

78

79

Figure 3-9.

Continued.
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Fhl2 Protein Levels in Skin
As evidenced by the phenotype, Tsk2/+ shows very tight skin and obvious ECM
fibrosis. We believe these phenotypic traits are caused by an excess of the Fhl2 protein.
Under the same experimental conditions, we measured Fhl2 protein levels in the skin of
Tsk2/+ and B6 littermates. We used all parts of the skin to measure the protein levels,
including the dermis and epidermis. Higher Fhl2 protein levels in Tsk2/+ compared to the
B6 mice verified that Tsk2/+ produces overexpression at the gene level compared to B6.
The protein expression was tested from four-week-old mice skin by western blot, and it
was found that the Fhl2 protein expression in Tsk2/+ mice is significantly more than that
observed in B6 mice of the same age (Figure 3-10). We duplicated the samples to ensure
that it was not an individual difference. We used ImageJ software to quantify the strength
of the band.
Gene Regulation of the Expression of Fhl2 in the Spleen
The genetic factors that regulate the expression of Fhl2 were measured on
GeneNetwork. With 2000 permutation testing, we found that the gene for regulating Fhl2
was on chromosome 5, and that the QTL on chromosome 5 was significant. The
significant LRS was 17.14 and suggestive LRS was 10.71. The QTL can reach the level
of 15 on Chromosome 5 (Figure 3-11A). The peak region of QTL on chromosome 5 was
between 55.00 to 64.00 Mb (Figure 3-11B). There were twenty-two genetic elements,
and eight of them were known genes. These were Pcdh7, G6pd2, Arap2, Gm336, Centd1,
Dthd1, Nwd2, and Rell1. From these gene networks, we gained understanding regarding
the upstream gene location and genetic pathway – from chromosome 5, from 55 to 65
Mb. The upstream gene of Fhl2 should be in this region.
Gene Network of Fhl2 in Mouse Spleen
The UTHSC Affy MoGene 1.0 ST Spleen (Dec10) RMA in GeneNetwork was
used to search the expression level data. The probe for Fhl2 and whole genome
expression profiles were compared in the spleen. From the top fifty probes, gene
expression levels correlated to Fhl2, and nineteen of them were known genes. There were
positive or negative correlations to Fhl2. The expression of Fhl2 was positively correlated
to translocate demilune cell and parotid protein1 (Dcpp1), kinocilin (Kncn), follistatin
(Fst), Lim homeobox protein 3 (Lhx3), amelogenin X chromosome (Amelx), predicted
gene 5246 (Gm5246), keratin 31 (Krt31), synaptotagmin-like 5 (Sytl5), trace amineassociated receptor 8A (Taar8a), CCR4-NOT transcription complex, subunit 8 (Cnot8),
defensin, alpha, related sequence 2 (Defa-rs2), transmembrane channel-like gene family 1
(Tmc1), H1 histone family, member O, oocyte-specific (H1foo), olfactory receptor 1505
(Olfr1505), calcyon neuron-specific vesicular protein (Caly), C1q and tumor necrosis
factor related protein 3 (C1qtnf3), extended synaptotagmin-like protein 3 (Esyt3), and
predicted gene 597 (Gm597). There was only one negative correlation: heterochromatin
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Figure 3-10. Western blot analysis of skin from Tsk2/+ and B6 mice.
Protein samples were collected from the skin of Tsk2/+ and B6 mice when they were 4
weeks old. Samples were duplicated with the Fhl2 antibody. The bands of the 4 week old
B6 mice were lighter than those of the Tsk2/+ mice. The intensity of the bands was
measured using Image J software. From the bar graph, the Tsk2/+ mice had significantly
higher expression levels of the Fhl2 protein than did the B6 mice.
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Figure 3-11. Detection of QTL for Fhl2 gene expression levels using RI strains.
(A) QTL detection that the upstream gene is on the chromosome 5. The numbers on top
of each figure indicate the chromosome number. Numbers on the left vertical axis
indicate the LRS values. The pink lines on the top indicate the threshold for the
significant level. Light grey lines indicate the threshold for the suggestive level. (B) On
chromosome 5, the region is between 55.00 Mb to 64.00 Mb. The location is shown
below the horizontal axis. Numbers to the left of the vertical axis are the LRS values. The
pink lines on the top indicate the threshold for the significant level. Light grey lines
indicate the threshold for the suggestive level.
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protein 1, binding protein 3(Hp1bp3) (Figure 3-12). There is only Taar8a gene on
chromosome 5 between 35 and 65 Mb.
Discussion
Collagen is very abundant in the body and is the protein that plays the most
important role in the fibrotic process of SSc. Previous studies have shown that Tsk2/+
mice develop skin tightness, display ECM anomalies, and produce high ANAs levels.
Tsk2/+ mice have a normal life expectancy in comparison to the wild type mice. Male
Tsk2/+ mice were bred with B6 females because Tsk2/+ females cannot breed. We
examined and quantified the disease signs during aging and in different tissues and
determined a causative role for the collagen accumulation in the fibrotic trait. Tsk1/+
mice develop a hunched posture as they age. The Tsk2/+ mice do not have a posture
change. To evaluate disease progression, we needed to find a reliable method to
determine and quantify disease severity. To eliminate the variability inherent in the
physical skin grabbing method, measuring the interscapular skin tightness was used to
quantify the disease. Tsk2/+ mice have noticeably tighter scapular skin than their
littermates after 3 weeks; it was difficult to gather the skin into a fold. No difference was
found between organ size and shape of the two mice strains when they were collected at
4, 6, and 10 weeks. The body length, tail length, body weight, and skin tightness were
measured for comparing the Tsk2/+ and B6 mice. The body length and tail length did not
show a significant difference between Tsk2/+ and B6 mice. This is expected because this
is a skin disease and should not affect the body or tail length. For the body length, males
were longer than the females in both strains, but there was no tail length difference
between male and female. Weight increased with age in both male and female. Males
were heavier than the females in both strains. Both genders of the Tsk2/+ mice were
lighter than their B6 littermates. The reason for this is unknown, but we speculate that it
may be due to the physically smaller bones and lower bone density of Tsk2/+ mice
compared to normal B6 mice[167]. The skin scores were measured by grabbing the
interscapular skin at different ages. The mice were measured the first time when they
were 3 weeks old. phenotype between Tsk2/+ and B6 was obviously different, and this
was an important basis to use to distinguish them. The capability to grasp the skin was
measured by placing the pulled skin against a ruler. B6 mice skin can be grasped ~ 1.7
cm and the Tsk2/+ mice skin can only be grasped ~ 0.7 cm. Upon contact with the skin,
you can tell the difference between the two mice strains. The skin of the B6 mice was
elastic and one could grab a substantial amount of skin. On the other hand, the skin of
Tsk2/+ mice was tight and one was unable to grab very much skin to pull. The skin has
some small variation before 7 weeks and is relatively stable during growth. Our goal was
to find the mutation gene in Tsk2/+ mice.
The mutation gene for Tsk2/+ was reported as Col3a1 the Jiménez group[168].
The Tsk2/+ mice were identified by a single nucleotide change on Col3a1 gene by the
Blankenhorn group in 2015[167]. There were three DNA sequence differences that were
Tsk2/+-specific. All three single nucleotide polymorphisms were at different regions.
Two SNPs were on the Gulp1 intron, and they did not change the Gulp 1 mRNA splicing
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Figure 3-12. Gene network among Fhl2 genes, which are upregulated or
downregulated in mice, constructed using expression profiles from spleen BXD
mouse strains.
The Fifty most related genes were collected to compare with Fhl2, nineteen of them are
known genes. The Taar8a gene is the only one related to Fhl2 and on the chromosome 5
between 35 and 65 Mb.
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and gene expression in the skin. These two SNPs cannot cause the mutation. The third
SNP was in the Col3a1 exon. Thymine changed to adenine at 45,378,353 on chromosome
1. This changed the amino acid from cysteine to serine in the Procollagen III amino
terminal propeptide segment. Four pairs of primers for PCR and rt-PCR were designed by
Primer 3 to identify the Tsk2/+ and normal mice. The pairs of primers for PCR were
Col3a1-dna-T and Col3a1-dna-N. The Primers for rt-PCR were Col3a1-T and Col3a1-N.
The Col3a1-dna-T and Col3a1-dna-N had the same reverse primer, only the forward
primers were different. The Col3a1-dna-T forward primer and the Col3a1-dna-N forward
primer had only a single nucleotide difference. The last single nucleotide of the Col3a1dna-T forward primer was A and the Col3a1-dna-T forward primer was T. Tsk2/+ and B6
strains were confirmed by using PCR (data not shown). On the mRNA level, samples 1-3
from 4wks-B6 skin and samples 4-6 from 4wks-Tsk/2+ were amplified by rt-PCR by
using the Col3a1-T-F and Col3a1-T/N-R pair of primers. In this instance, when we
amplified the segment of DNA, Col3a1-dna-N can amplify both B6 and Tsk2/+, while
Col3a1-dna-T can only amplify Tsk2/+. Our data verified there is an SNP on Col3a1.
Verifying the B6 and Tsk2/+ mice by PCR and rt-PCR experiments can prove that there
is a single nucleotide polymorphism in Tsk2/+ in Col3a1 gene.
The single nucleotide polymorphism of thymine to adenine in Col3a1 was one
difference between B6 and Tsk2/+. The changing of this single nucleotide causes the
amino acid to change from cysteine to serine, and this changed the protein structure.
Cysteine and serine are both neutral-polar amino acids with similar structures. The only
difference in structure between the two amino acids is a change from a sulfhydryl (SH) to
a hydroxyl (OH) group. We believe that this a negligible difference that makes only a
limited change in protein structure or function. The Col3a1 expression levels were not
different between B6 and Tsk2/+ mice in skin, heart, and kidney. There is only one
transcript of the Col3a1 gene. If Col3a1 is the mutation gene, why is there fibrosis only in
the skin, not other tissues or organs? According to an online database, bladder,
mammary, osteoblast, and umbilical had very high expression levels. Why was there not
any report of these tissues having fibrosis? If Col3a1 is the only mutated gene, then
fibrosis should be found throughout the body, not just in the skin. However, fibrosis has
not been reported in other organs; thus, in our hypothesis, there must be at least one other
mutation gene influencing susceptibility to tight skin disease. Based on this, there is
another regulatory gene that could be found by examining upregulation in Tsk2/+. The
upregulated genes were of interest because we knew that the collagen level increased in
tight skin and that this was caused by overexpression. In our microarray data, there were
eighty-two probes upregulated in Tsk2/+ and four probes upregulated on chromosome 1
between 42.5 and 52.5 Mb. The four genes were Col3a1, Slc40a1, Slc39a10, and Fhl2.
Based on our many years of research, Fhl2 was chosen as our candidate gene.
Of the four upregulated genes, the Col3a1 and Fhl2 have had expression levels
tested in different tissues, because Col3a1 had been previously reported as a candidate
gene, and Fhl2 is located on the QTL region. Col3a1 and Fhl2 are both located on
chromosome one. These two genes are expressed in different tissues, and within the
tissues in which they are expressed, their expression levels are different. Since Col3a1
only has one transcript, fibrosis would be expected to be found in the tissues where there
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is high expression, but it is not. The high expression of Fhl2 in the heart can be explained
by Fhl2 having two transcripts and only one of them being the cause of tight skin.
Fhl2 is located on chromosome 1 from 43,123,074 to 43,196,984. In our research,
there were two protein coding transcripts: Fhl2-201 and Fhl2-202. Fhl2-201 was
determined to be 1566 bp and Fhl2-202 was 1417 bp. The difference in these two
transcripts is that they have different first exons. The first exons are completely different
fragments between the two transcripts, not just that Fhl2-201 is 149 bp longer than Fhl2202. The rest of the five exons were identical. The two transcripts displayed different
expression ratios in different tissues and organs, and many tissues and organs only
showed expression of one of the transcripts. Although the first exon is different, these
two transcripts produce the same protein, but the promoters are different. So, although the
same protein is being expressed by these transcripts, the amount of protein produced will
be different because of the promoters. A mutation in the promoter of Fhl2-201 could be
the cause of upregulation in Tsk2/+, causing tight skin. The expression levels of the two
transcripts are relatively independent. In our experiments, the two transcripts, Fhl2-201
and Fhl2-202, were tested for expression levels in skin, muscle, heart, kidney, liver, and
lung. From the results of our experiments, skin and kidney only showed Fhl2-201
transcript expression. As shown in Table 3-1, the expression of Fhl2 is very low in the
kidney and likely does not cause fibrosis. The heart had mainly Fhl2-202 transcript
expression and subtle Fhl2-201 transcript expression. In muscle, liver, and lung, both
transcripts had no or very low expression. It is clear that the expression level of the Fhl2201 transcript in the skin is much higher for the Tsk2/+ mice than that of the B6 mice.
The heart expresses Fhl2-202 but not Fh12-201, so the high expression of the gene does
not affect the heart. These results explain why fibrosis is only found in the skin, and why
expression of Fhl2-201 is low or nonexistent in the other organs compared to high
expression in the skin.
In our study, we thought there was a single or only a few single nucleotide
polymorphisms on the Fhl2 gene. We designed many primers to amplify the segments in
order to sequence them and identify the polymorphisms. We sequenced the genomic
DNA, cDNA, promoter, and two side introns connecting each exon. We have not yet
found a polymorphism between B6 and Tsk2/+. We will increase the scope of sequencing
to find the polymorphisms. Since a polymorphism was not found, upstream genes were
identified as other possibilities to study. Taar8a was found upstream of Fhl2 and is on
chromosome 5. This can be beneficial in the quest to understand the molecular
mechanism and pathway of Tsk2/+.
Real-time PCR was used to detect the expression levels in different tissues and
organs. Probes were ordered from Applied Biosystems, so we did not know which part of
the gene they selected. The Fhl2 gene expression levels in Tsk2/+ mice were higher than
that of B6 mice, and the expression variability increased with age. The Fhl2 gene
expression levels were tested in different tissues at 4, 6, and 10 weeks in female mice. In
the skin, the Fhl2 expression levels of Tsk2/+mice were higher than that of B6 mice at all
the same time points. At 4 and 6 weeks, Tsk2/+ were around 1.5-fold more than normal.
At 10 weeks, the Tsk2/+ expression level was 2.5-fold more than normal. In the muscle,
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heart, kidney, and lung tissues, the Fhl2 expression levels were slightly higher in Tsk2/+
than B6. The expression of Fhl2-202 in Tsk2/+ and B6 tissues or organs were the same.
The Fhl2-201 gene expression levels were different among Tsk2/+ and B6 tissues and
organs. In the skin, the Fhl2 gene mainly expresses the Fhl2-201 transcript, so there was a
clear difference between Tsk2/+ and B6 in real-time PCR. In muscle, heart, kidney, and
lung, we found that the Fhl2 expression levels in Tsk2/+ were higher than B6, but the
difference very minor. Both Fhl2-201 and Fhl2-202 were present in these tissues or
organs, but Fhl2-202 accounted for a more dominant role. Fhl2-201 is suspected as being
the mutated gene and not Fhl2-202 as supported by these data because the RT results
showed that there was no difference in Fhl2-202 between Tsk2/+ and B6, but there is a
difference in Fhl2-201. Through Western blot experiments, we measured Fhl2 protein
levels to substantiate our position. The protein levels of Fhl2 in Tsk2/+ skin were higher
than that found in B6 skin.
This study identified Fhl2 as a possible candidate gene for Tsk2/+, but the
research on this gene and its role in the disease is not yet complete. Even if this gene is
not the mutated gene, it has very important implications in the molecular mechanism and
pathway for this disease. We have not yet found the SNP between the Tsk2/+ and B6
mice yet, but Fhl2 is clearly a very important gene for the disease.
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CHAPTER 4.

CONCLUSION

Diseases of the immune system are a very important issue. They are always very
complicated because they have multiple influencing factors. Currently, there are at least
80 known autoimmune diseases, of which rheumatoid arthritis and systemic sclerosis are
two. Arthritis and systemic sclerosis are serious, debilitating autoimmune diseases that
collectively affect over fifty-five million people in just the United States. Rheumatoid
arthritis is a systemic, chronic, inflammatory disorder that is expressed in the wrists,
ankles, and small joints of the hands and feet that can cause pain and swelling. Systemic
sclerosis is a localized or diffuse skin thickening and fibrosis caused by the body’s
immune system attacks its own tissue. This disease is a debilitating, chronic autoimmune
disease that is potentially fatal, but the underlying cause is unknown. Limited cutaneous
and diffuse cutaneous are the two main types of system sclerosis. In past six years, I used
our two disease mouse models to improve the understanding of the human diseases. This
study aimed to evaluate the molecular mechanisms of these two diseases by studying
wild type and mutated genes in mouse models. Understanding the molecular
mechanisms that lead to these diseases is of great importance for discovering therapeutic
remedies and possibly preventing or curing the RA and systemic sclerosis.
Spontaneous arthritis was studied in mice because of the strong similarities found
between arthritis in humans and in mice. We discovered the candidate genes in our IL1rn deficient spontaneous arthritis mouse models to understand the pathogenesis and
treatment of inflammatory arthritis. The model is of interest because it is spontaneous in
onset and involves a signaling pathway implicated in human arthritis. Fully
understanding the model may provide insight into what triggers disease and ultimately
how to prevent arthritis. To better understand the pathogenesis of SAD, we bred
susceptible, resistant and congenic mice: BALB/c-/-, DBA/1-/-, BALB.D-1-/-, and DBA.B1-/-. Our study produced useful data on the genetic regulation of spontaneous arthritis
under the BALB/c-/- and DBA/1-/- genomic background. The QTLs and the information
on candidate genes provide a basic analysis of the molecular mechanisms of spontaneous
arthritis. We located a genetic factor that regulates SAD on chromosome 1. The
expression levels of Ifi200 cluster genes were decreased while the resistance to SAD is
increased in the congenic strain BALB.D1-1-/-, in comparison to its recipient parental
strain BALB/c-/-. The expression level of Ifi204 is the only gene in the Ifi200 cluster
which showed a significant difference at a detectable or functional level, suggesting
Ifi204 within the QTL region is most likely the causal gene for the regulation of SAD
between mice with BALB/c-/- and DBA/1-/- genomic background. We sequenced the
coding gene between BALB/c-/- and DBA/1-/- mice and found several polymorphisms.
The function of the protein may be changed by alterations in the protein structure that is
modified by the polymorphisms. In future studies, we will compare the specific protein
structure between BALB/c-/- and DBA/1-/- by first getting a complete sequence of the
genes to compare. The difference in protein structure can help us understand why the two
strains do or do not have arthritis when they lack IL-1rn. Through this research we were
able to determine a genetic component that regulates susceptibility to SAD, and then
identify Ifi204 as a candidate gene in the causal pathway of spontaneous arthritis. The
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theory that Ifi204 is a favorable candidate gene is supported by the results. They show
that the expression levels of Ifi204 decreased while resistance to SAD increased, but the
expression levels increased in relation to a decrease in SAD resistance. This data can be
used to further study Ifi204 and its relationship with spontaneous arthritis in hopes of
developing a drug that targets Ifi204.
Systemic sclerosis (SSc) or scleroderma is a prototypic idiopathic fibrosing
disease. These fibrotic diseases are influenced by many environmental and genetic factors
and have been extensively studied. However, many of the basic mechanisms of disease
pathogenesis remain elusive. There are only a few effective therapies for preventing
fibrosis. We used a mouse autoimmune disease model called tight skin 2 (Tsk2) to study
genetic factors that regulate fibrosis in dermal tissues. Tsk2/+ is a mouse model
containing a mutation that causes tight skin and excessive deposition of dermal ECM
proteins, a presentation very similar to that of systemic sclerosis in humans, and thus
making it a perfect animal model to study the molecular mechanism of the disease.
Studies indicated that excess collagen production was the result of an increased number
of collagen expressing dermal fibroblasts, as well as elevated collagen expression on a
per cell basis. We focused on identifying the mutated gene in the disease locus of the
Tsk2/+ mouse. The mutation has been localized to mouse chromosome 1 between 42.5
and 52.5 megabases (Mb), and considerable effort has been expended in the study of the
molecular mechanisms of the disease. We used data from microarray expression profiles
to select candidate genes. A single nucleotide polymorphism was found in COL3A1
between the diseased model (Tsk2/+) and the normal model (B6) that results in a change
in protein structure. From the microarray data and gene mapping, Fhl2 gene was found to
be the potential candidate gene. We confirmed Fhl2 gene expression levels were different
in Tsk2/+ and normal mice skin by PCR, rt-PCR and real time PCR. There are two
transcripts of the Fhl2 gene and each transcript is expressed in different tissues which
explains why only the skin has fibrosis. We hypothesized that there would be one or more
nucleotide polymorphisms between Tsk2/+ and B6 in this gene, but one has not been
found. We intend to increase the scope to find the polymorphism(s). In future studies, we
will increase our sequencing region and carefully examine the data to make sure we do
not miss any potential heterozygotes in Tsk2 mice. We will search the molecular pathway
to understand the genes upstream and downstream of the Fhl2 gene.
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